<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochemistry</journal-id><journal-id journal-id-type="iso-abbrev">Biochemistry</journal-id><journal-id journal-id-type="publisher-id">bi</journal-id><journal-id journal-id-type="coden">bichaw</journal-id><journal-title-group><journal-title>Biochemistry</journal-title></journal-title-group><issn pub-type="ppub">0006-2960</issn><issn pub-type="epub">1520-4995</issn><publisher><publisher-name>American
Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29485857</article-id><article-id pub-id-type="pmc">PMC6007964</article-id><article-id pub-id-type="doi">10.1021/acs.biochem.7b01299</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Structural and Kinetic Studies of the Potent Inhibition
of Metallo-&#x003b2;-lactamases by 6-Phosphonomethylpyridine-2-carboxylates</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Hinchliffe</surname><given-names>Philip</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Tanner</surname><given-names>Carol A.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Krismanich</surname><given-names>Anthony P.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Labb&#x000e9;</surname><given-names>Genevi&#x000e8;ve</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Goodfellow</surname><given-names>Valerie J.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Marrone</surname><given-names>Laura</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Desoky</surname><given-names>Ahmed Y.</given-names></name><xref rid="aff6" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Calvopi&#x000f1;a</surname><given-names>Karina</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Whittle</surname><given-names>Emily E.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Zeng</surname><given-names>Fanxing</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Avison</surname><given-names>Matthew B.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath12"><name><surname>Bols</surname><given-names>Niels C.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath13"><name><surname>Siemann</surname><given-names>Stefan</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath14"><name><surname>Spencer</surname><given-names>James</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath15"><name><surname>Dmitrienko</surname><given-names>Gary I.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><aff id="aff1"><label>&#x02020;</label>School
of Cellular &#x00026; Molecular Medicine, <institution>University
of Bristol</institution>, Bristol BS8 1TD, <country>U.K.</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Chemistry, <institution>University of Waterloo</institution>, Waterloo, Ontario, <country>Canada</country> N2L 3G1</aff><aff id="aff6"><label>&#x000b6;</label>Department
of Chemistry, College of Science, <institution>University
of Hail</institution>, <country>Saudi Arabia</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Biology, <institution>University of Waterloo</institution>, Waterloo, Ontario, <country>Canada</country> N2L 3G1</aff><aff id="aff4"><label>&#x02225;</label>Department
of Chemistry and Biochemistry, <institution>Laurentian
University</institution>, Sudbury, Ontario, <country>Canada</country> P3E 2C6</aff><aff id="aff5"><label>&#x022a5;</label>School
of Pharmacy, <institution>University of Waterloo</institution>, Waterloo, Ontario, <country>Canada</country> N2L 3G1</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>dmitrien@uwaterloo.ca</email>.</corresp><corresp id="cor2"><label>*</label>E-mail: <email>jim.spencer@bristol.ac.uk</email>.</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>02</month><year>2018</year></pub-date><pub-date pub-type="ppub"><day>27</day><month>03</month><year>2018</year></pub-date><volume>57</volume><issue>12</issue><fpage>1880</fpage><lpage>1892</lpage><history><date date-type="received"><day>28</day><month>12</month><year>2017</year></date><date date-type="rev-recd"><day>15</day><month>02</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 American Chemical Society</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license><license-p>This is an open access article published under an ACS AuthorChoice <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0007" id="ab-tgr1"/></p><p>There
are currently no clinically available inhibitors of metallo-&#x003b2;-lactamases
(MBLs), enzymes that hydrolyze &#x003b2;-lactam antibiotics and confer
resistance to Gram-negative bacteria. Here we present 6-phosphonomethylpyridine-2-carboxylates
(PMPCs) as potent inhibitors of subclass B1 (IMP-1, VIM-2, and NDM-1)
and B3 (L1) MBLs. Inhibition followed a competitive, slow-binding
model without an isomerization step (IC<sub>50</sub> values of 0.3&#x02013;7.2
&#x003bc;M; <italic>K</italic><sub>i</sub> values of 0.03&#x02013;1.5
&#x003bc;M). Minimum inhibitory concentration assays demonstrated potentiation
of &#x003b2;-lactam (Meropenem) activity against MBL-producing bacteria,
including clinical isolates, at concentrations at which eukaryotic
cells remain viable. Crystal structures revealed unprecedented modes
of binding of inhibitor to B1 (IMP-1) and B3 (L1) MBLs. In IMP-1,
binding does not replace the nucleophilic hydroxide, and the PMPC
carboxylate and pyridine nitrogen interact closely (2.3 and 2.7 &#x000c5;,
respectively) with the Zn2 ion of the binuclear metal site. The phosphonate
group makes limited interactions but is 2.6 &#x000c5; from the nucleophilic
hydroxide. Furthermore, the presence of a water molecule interacting
with the PMPC phosphonate and pyridine N&#x02013;C2 &#x003c0;-bond, as
well as the nucleophilic hydroxide, suggests that the PMPC binds to
the MBL active site as its hydrate. Binding is markedly different
in L1, with the phosphonate displacing both Zn2, forming a monozinc
enzyme, and the nucleophilic hydroxide, while also making multiple
interactions with the protein main chain and Zn1. The carboxylate
and pyridine nitrogen interact with Ser221 and -223, respectively
(3 &#x000c5; distance). The potency, low toxicity, cellular activity,
and amenability to further modification of PMPCs indicate these and
similar phosphonate compounds can be further considered for future
MBL inhibitor development.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>bi7b01299</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>bi-2017-01299s</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Antibacterial
drug resistance
is an increasingly major clinical problem, particularly because of
the reduced efficacy of &#x003b2;-lactam antibiotics against Gram-negative
pathogens such as <italic>Escherichia coli</italic>, <italic>Klebsiella
pneumoniae</italic>, <italic>Pseudomonas aeruginosa</italic>, and <italic>Stenotrophomonas maltophilia</italic>.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> &#x003b2;-Lactams
remain key agents for treatment of Gram-negative infections, with
the carbapenems and third-generation cephalosporins being the first-choice
chemotherapeutic agents. Among the major resistance determinants are
zinc-dependent metallo-&#x003b2;-lactamases (MBLs), zinc-dependent enzymes
that hydrolyze almost all &#x003b2;-lactams, including the carbapenems
and cephalosporins.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref6">6</xref></sup> MBLs all have a similar overall fold with the active site lying
in a groove formed by two &#x003b2; sheets but are subdivided into three
subclasses (B1&#x02013;B3) based on the sequence, the structure, and
the number of zinc ions in their active site.<sup><xref ref-type="bibr" rid="ref7">7</xref>&#x02212;<xref ref-type="bibr" rid="ref10">10</xref></sup> In B1 and B3 MBLs, the active
site contains two zinc ions, Zn1 coordinated by His116, His118, and
His196 (standard MBL numbering scheme<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> used
throughout) and Zn2 coordinated by Asp120, His263, and either Cys221
in the B1 subclass or His121 in the B3 subclass. A water/hydroxide
bridges/coordinates the two zinc ions and is thereby potentially activated
to act as a nucleophile to attack the &#x003b2;-lactam ring.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> By comparison, subclass B2 MBLs are active as
monozinc enymes, with the single zinc ion coordinated by Asp120, Cys221,
and His263 in an architecture similar to that of the Zn2 site in B1
MBLs.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> In contrast to the serine-&#x003b2;-lactamases
(SBLs),<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> there are currently no clinically
useful MBL inhibitors. The differences between the various MBL active
sites have hindered the development of inhibitors active against all
MBLs.</p><p>MBL inhibitor design has focused on compounds that include
metal-binding
moieties such as nitrogen, thiols, and carboxylates or compounds that
mimic hydrolysis intermediates, such as the bicyclic boronates.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> The various thiols are the best studied, with
captopril, a molecule containing both a thiol and carboxylate group,
being the most prominent example. The <sc>d</sc>- and <sc>l</sc>-stereoisomers
of captopril are variously effective against B1 and B3 MBLs with IC<sub>50</sub>&#x02019;s covering a wide range, from 0.072 to &#x0003e;500 &#x003bc;M,
depending on the captopril stereoisomer and MBL variant.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> X-ray crystal structures show the thiol group
bridges the two active site zinc ions of B1 and B3 MBLs, while in
B2 MBLs, the carboxylate interacts with the Zn2 site,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> with the thiol group being uninvolved. More recently, we
described bisthiazolidines<sup><xref ref-type="bibr" rid="ref16">16</xref>&#x02212;<xref ref-type="bibr" rid="ref18">18</xref></sup> that contain not only a thiol
group but also nitrogen and carboxylate moieties and can inhibit B1
enzymes such as NDM-1 (<italic>in vivo</italic> IC<sub>50</sub>&#x02019;s
of 23&#x02013;201 &#x003bc;M), again through a zinc-bridging thiol group.
The carboxylate group of both captoprils and bisthiazolidines can
also interact with residues on the protein main chain (Lys224 or Ser221
in B1 or B3 enzymes, respectively) that have previously been shown
to bind a hydrolyzed substrate.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> A number of other crystal
structures of thiols bound to MBLs show similar binding modes, with
the thiol bridging the two zincs in B1<sup><xref ref-type="bibr" rid="ref21">21</xref>&#x02212;<xref ref-type="bibr" rid="ref24">24</xref></sup> and B3<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> MBLs, and a carboxylate<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> or the thiol<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> binding to the
monozinc center of B2 MBLs.</p><p>The modes of binding of potent (IC<sub>50</sub> values ranging
between 0.003 and 7 &#x003bc;M<sup><xref ref-type="bibr" rid="ref13">13</xref></sup>) dicarboxylate
MBL inhibitors are also well-understood, with crystal structures available
of such compounds bound to all three MBL subclasses: biaryl succinic
acid<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> and 3-aminophthalic acid<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> to the B1 enzyme IMP-1, 2,4-pyridine dicarboxylic
acid to <italic>Aeromonas hydrophila</italic> CphA (B2),<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and furan/pyrazole-constrained dicarboxylic
acids to <italic>S. maltophilia</italic> L1 (B3).<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> In all cases, binding is similar to that of thiols, with
one carboxylate moiety bridging the two active site zinc ions and
the second carboxylate interacting with a Ser or Lys residue. In the
case of dicarboxylate inhibition of the B2 MBL CphA, only one of the
two carboxylates is involved in active site interactions, binding
the zinc ion, although the nitrogen of the pyridine ring also ligands
the zinc ion. Nitrogen-based inhibition, by tetrazole-based ligands
(IC<sub>50</sub> &#x0223c; 18&#x02013;300 &#x003bc;M<sup><xref ref-type="bibr" rid="ref28">28</xref></sup>) and 4-nitrobenzene-sulfonamide (IC<sub>50</sub> not reported),
has also been structurally characterized in B1 (<italic>Bacteroides
fragilis</italic> CcrA<sup><xref ref-type="bibr" rid="ref31">31</xref></sup>) and B3 (<italic>Bradyrhizobium japonicum</italic> BJP-1<sup><xref ref-type="bibr" rid="ref32">32</xref></sup>) MBLs. In both cases, inhibition is achieved by interaction of an
inhibitor nitrogen with either the Zn2 site only (CcrA) or both Zn1
and Zn2 (BJP-1).</p><p>Bicyclic boronates are proposed to mimic the
tetrahedral oxyanion
formed during &#x003b2;-lactam hydrolysis.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> They inhibit B1 enzymes (IC<sub>50</sub>&#x02019;s of 0.003&#x02013;1
&#x003bc;M) through interaction of the &#x0201c;exocyclic&#x0201d; boronate
oxygen within the dizinc center, displacing the nucleophilic hydroxide,
and the &#x0201c;endocylic&#x0201d; boronate ester oxygen with Zn2.
As with other inhibitors, the carboxylate interacts with both Zn2
and Lys224 (e.g., NDM-1) or Arg228 (e.g., VIM-2) on the protein main
chain. The bicyclic boronates do not inhibit the B3 enzymes, such
as <italic>S. maltophilia</italic> L1.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></p><p>Less well understood is MBL inhibition by compounds containing
phosphonate, a moiety well-known to chelate zinc and inhibit metalloenzymes.<sup><xref ref-type="bibr" rid="ref35">35</xref>&#x02212;<xref ref-type="bibr" rid="ref37">37</xref></sup> In addition, phosphonate monoesters have been shown to inhibit SBLs
by formation of a tetrahedral intermediate mimic covalently bound
to the active site serine.<sup><xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup> Mercaptophosphonate
compounds, which contain both a phosphonate and a thiol group, have
been reported as competitive inhibitors of all MBL classes, with <italic>K</italic><sub>i</sub> values from 0.4 to &#x0003e;400 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Indeed, in the crystal structure of a mercaptophosphonate:B2
CphA complex, the phosphonate preferentially binds the zinc ion over
the thiol group.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> There is potential of
phosphonates to act as analogues of mechanistically important oxyanionic
species in MBL-catalyzed &#x003b2;-lactam hydrolysis. A recent study
of a &#x003b2;-phospholactam (containing a cyclic phosphonamidate, which
might undergo hydrolysis to a phosphonate in aqueous medium) exhibited
modest time-dependent inhibition of B1 and B3 MBLs at 100 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> However, to date, the utility of phosphonates
as broad-spectrum inhibitors active against multiple MBL subclasses
remains underexplored. Accordingly, here we investigate phosphonate-based
pyridine-carboxylates [PMPCs (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>)] as inhibitors of clinically relevant B1 and B3 MBLs.
Our data show that these compounds inhibit a range of MBL targets
and, through X-ray crystallography and kinetic experiments, define
their mode of binding to, and mechanism of inhibition of, target B1
and B3 MBLs. Importantly, we also demonstrate potentiation of &#x003b2;-lactam
antibacterial activity against both laboratory and clinical strains
of MBL-producing bacteria, suggesting that these compounds may be
useful against medically relevant antibiotic resistant pathogens.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Structures
of pyridine-2-carboxylates used in this study: (<bold>1</bold>) PA,
2-picolinic acid; (<bold>2</bold>) MPA, 6-methylpicolinic
acid; (<bold>3a</bold>) PMPC-1, 6-(phosphonomethyl)pyridine-2-carboxylate;
(<bold>3b</bold>) PMPC-2, 6-[hydroxy(phosphono)methyl]picolinic acid;
(<bold>3c</bold>) PMPC-3, 6-[(<italic>N</italic>-benzyl-1-thiophen-2-ylformamido)(phosphono)methyl]picolinic
acid; (<bold>4</bold>) (pyridin-2-ylmethyl)phosphonic acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0001" id="gr1" position="float"/></fig><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>Materials</title><p>All
reagent chemicals used in synthesis,
including 2-picolinic acid (<bold>1</bold>) and 6-methyl-2-picolinic
acid (<bold>2</bold>), were acquired from Sigma-Aldrich (Canada) and
were employed as received. Nitrocefin was obtained from Oxoid or prepared
synthetically as described previously.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup></p></sec><sec id="sec2.2"><title>Inhibitor Synthesis</title><p>The synthesis and characterization
of PMPC-1 (<bold>3a</bold>) have been reported previously.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> The synthesis and spectroscopic characterization
of PMPC-2 (<bold>3b</bold>), PMPC-3 (<bold>3c</bold>), and PMP (<bold>4</bold>) are described in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Supporting Information</ext-link>.</p></sec><sec id="sec2.3"><title>Minimum Inhibitory Concentration Assays</title><sec id="sec2.3.1"><title>Bacterial Strains and Plasmids</title><p>Open reading frames,
together with the associated promoter sequences, encoding the IMP-1,
VIM-1, and NDM-1 MBLs were amplified from clinical samples by polymerase
chain reaction (PCR) and cloned into the pSU18 broad host range vector
as previously described.<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup><italic>E. coli</italic> MG1655, <italic>K. pneumoniae</italic> Ecl8, <italic>Citrobacter
freundii</italic>, and <italic>Enterobacter aerogenes</italic> were
transformed with the resulting plasmids by electroporation. <italic>K. pneumoniae</italic> strain UWB116 (N11-2218) (as recently employed
in a study of the natural product aspergillomarasmine A<sup><xref ref-type="bibr" rid="ref44">44</xref></sup>) was a generous gift from A. McGeer at Mount
Sinai Hospital (Toronto, ON). <italic>P. aeruginosa</italic> strain
UWB41 (IS6654) and <italic>S. maltophilia</italic> strain UWB26 (IS5563)
are Meropenem resistant strains kindly provided by D. Pillai from
the collection of clinical isolates maintained at the Ontario Agency
for Health Protection and Promotion (now known as Public Health Ontario,
Toronto, ON). <italic>P. aeruginosa</italic> strain UWB78 (VIM-I-1;
03-RL-03-2453), <italic>Pseudomonas putida</italic> strain UWB24 (C10;
PS679/00), <italic>E. coli</italic> strain UWB75 (MH1-NDM-1), and <italic>E. coli</italic> strain UWB93 (Ec7-IMP) originated from the collection
of clinical isolates maintained at Calgary Laboratory Services (Calgary,
AB) and were kindly provided by J. Pitout and D. Pillai. <italic>S.
maltophilia</italic> strains K279a, K ami32 (efflux pump overproducing
mutant), and JKWZP (knockout strain lacking the RND pumps SmeJ/K/W/Z/P)
were described previously.<sup><xref ref-type="bibr" rid="ref45">45</xref>&#x02212;<xref ref-type="bibr" rid="ref47">47</xref></sup> For all strains, species identification
and the presence of specific MBLs were confirmed by PCR using 16S
rDNA and MBL-specific primers, respectively.</p></sec><sec id="sec2.3.2"><title>Minimum Inhibitory Concentration
(MIC) Determination</title><p>MIC values were determined by broth microdilution,
in triplicate,
in cation-adjusted Mueller Hinton broth (Sigma) according to the Clinical
Laboratory Standards Institute (CLSI) guidelines.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> Experiments were performed in microtiter plates (Corning)
containing the medium with Meropenem and inhibitor [dissolved in dimethyl
sulfoxide (DMSO)] as appropriate. Plates were incubated overnight
at 37 &#x000b0;C for 18&#x02013;24 h, and the absorbance at 600 nm was
read using Polarstar Omega (BMG LabTech) or Powerwave XS2 (Biotek)
plate readers.</p></sec></sec><sec id="sec2.4"><title>Cell Toxicity Assay</title><sec id="sec2.4.1"><title>Cell Culture</title><p>The
mammalian cell lines were rat liver
hepatoma cell line H4IIE (ATCC catalog no. CRL-1600) and two human
cell lines, Caco2, a colon adenocarcinoma cell line (ATCC catalog
no. HTB-37), and HepG2, a liver hepatoma cell line (ATCC catalog no.
CRL-11997). Cells were routinely cultured in Dulbecco&#x02019;s modified
Eagle&#x02019;s medium (DMEM, Sigma) supplemented with 10% fetal bovine
serum (FBS) in 75 cm<sup>2</sup> vented culture flasks at 37 &#x000b0;C
in a humidified 5% CO<sub>2</sub> atmosphere.</p></sec><sec id="sec2.4.2"><title>Plating and
Dosing</title><p>Cells were seeded in 96-well plates
(Becton and Dickinson Co., Franklin Lakes, NJ) at a density of 4 &#x000d7;
10<sup>4</sup> cells per well in 200 &#x003bc;L of DMEM growth medium
with a 10% FBS supplement. Cells were allowed to settle and reattach
for 24 h at room temperature before being exposed to any compounds.
The cells were then dosed with varying concentrations of <bold>3a</bold> in DMEM without 10% FBS. Application of chemicals to cell cultures
was done by adding culture medium mixed with the chemical solution
to the culture well. The final concentration of the solvents (such
as DMSO or water) in each well was the same as for the control wells,
which were dosed with only solvent. After 24 h, cultures were evaluated
for cytotoxicity. In no cases was the solvent used at a concentration
that was cytotoxic.</p></sec><sec id="sec2.4.3"><title>Measuring Cell Viability</title><p>Three fluorescent
indicator
dyes were used to evaluate cell viability.<sup><xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref50">50</xref></sup> Metabolic activity was measured by Alamar Blue (Medicorp, Montreal,
QC). Cell membrane integrity was evaluated with 5-carboxyfluorescein
diacetate (CFDA-AM) (Molecular Probes, Eugene, OR). Lysosome integrity
was monitored with Neutral Red (Sigma-Aldrich). Alamar Blue, CFDA-AM,
and Neutral Red were prepared in Dulbecco&#x02019;s phosphate-buffered
saline (DPBS, Lonza, Walkersville, MD) to give final concentrations
of 5% (v/v), 4 &#x003bc;M, and 1.5% (v/v), respectively. Cells were
incubated with dyes for 1 h in the dark and then quantified with a
fluorescence plate reader (Spectra-max Gemini XS microplate spectrofluorometer;
Molecular Devices, Sunnyvale, CA). The excitation and emission wavelengths
used were 530 and 590 nm for Alamar Blue, 485 and 530 nm for CFDA-AM,
530 and 640 nm for Neutral Red, respectively. Results were calculated
as a percent of the control culture.</p></sec><sec id="sec2.4.4"><title>Data Analysis</title><p>All graphs were created and statistical
analyses performed using GraphPad InStat (version 4.01 for Windows
XP, GraphPad Software, San Diego, CA).</p></sec></sec><sec id="sec2.5"><title>Protein Purification</title><p>NDM-1, VIM-2, IMP-1, and L1 were
purified as previously described.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref51">51</xref>&#x02212;<xref ref-type="bibr" rid="ref53">53</xref></sup></p></sec><sec id="sec2.6"><title>Enzyme Kinetics</title><p>All data analysis of enyme kinetics
was performed using GraphPad Prism version 5.00 for Windows (GraphPad
Software).</p><sec id="sec2.6.1"><title>IC<sub>50</sub> Assays</title><p>Inhibitor stocks were prepared
by dissolving the PMPC compound in 100% DMSO to a final concentration
of 100 mM. Compound PMP stocks were prepared as 50 mM compound in
50 mM HEPES (pH 7.2).</p><p>The enzyme (IMP-1, 186 pM; VIM-2, 313
pM; NDM-1, 620 pM; L1, 637 pM) in the standard assay mixture [50 mM
HEPES (pH 7.2), 50 &#x003bc;g/mL BSA, and 0.01% Triton X-100] was incubated
with the inhibitor for 10 min at 30 &#x000b0;C and then added to nitrocefin
at concentrations resembling or identical to the <italic>K</italic><sub>M</sub> value for this substrate (IMP-1, 3.5 &#x003bc;M; VIM-2,
15 &#x003bc;M; NDM-1, 1.0 &#x003bc;M; L1, 5.0 &#x003bc;M). Same day triplicates
of assays performed in 96-well flat-bottom microplates (Corning, Corning,
NY) were read at 482 nm for 5 min at 30 &#x000b0;C using a Spectramax
190 reader (Molecular Devices, Sunnyvale, CA).</p><p>Measurements
for each compound were performed on three or four
different days unless otherwise indicated. IC<sub>50</sub> values
were obtained by fitting <xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula">1</xref></xref> to the recorded initial velocities using nonlinear least-squares
regression.<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_m001" position="anchor"/><label>1</label></disp-formula>where <italic>y</italic> is
the measured initial rate, [I] is the inhibitor concentration, and <italic>s</italic> is the Hill slope.</p></sec><sec id="sec2.6.2"><title><italic>K</italic><sub>i</sub> Determination</title><p>The enzyme
(60 pM IMP-1, 39.2 pM VIM-2, 600 pM NDM-1, or 308 pM L1) was added
to nitrocefin in excess of enzyme (25 &#x003bc;M for IMP-1, 100 &#x003bc;M
for VIM-2, 15 &#x003bc;M for NDM-1, and 50 &#x003bc;M for L1) containing
various dilutions of inhibitor from the range of variable rates as
determined from IC<sub>50</sub> experiments. The assay was performed
in 50 mM HEPES (pH 7.2) supplemented with 50 &#x003bc;g/mL BSA and 0.01%
Triton X-100 in 96-well flat-bottom microplates to a final volume
of 200 &#x003bc;L. All assays were read at 482 nm using a SpectraMax
190 plate reader at 30 &#x000b0;C for 10 min. Progress curves were fitted
by nonlinear regression to <xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula">2</xref></xref>:<sup><xref ref-type="bibr" rid="ref54">54</xref>,<xref ref-type="bibr" rid="ref55">55</xref></sup><disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_m002" position="anchor"/><label>2</label></disp-formula>where [P]<sub><italic>t</italic></sub> is
the product concentration at time <italic>t</italic>, <italic>v</italic><sub>0</sub> and <italic>v</italic><sub>s</sub> are the initial and
steady-state velocities, respectively, <italic>k</italic><sub>obs</sub> is the apparent first-order rate constant for the development of
the steady state, and <italic>C</italic> is included to correct for
deviations of the baseline. Values of <italic>k</italic><sub>obs</sub> obtained at multiple concentrations of inhibitor [I] were then plotted
against [I], and the result was fitted to a straight line defined
by <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula">3</xref></xref>:<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_m003" position="anchor"/><label>3</label></disp-formula>where <italic>k</italic><sub>&#x02013;0</sub> is the dissociation rate constant for the enzyme:inhibitor complex
EI and <italic>K</italic><sub>i</sub><sup arrange="stack">app</sup> is the apparent inhibition constant. Finally, <italic>K</italic><sub>i</sub><sup arrange="stack">app</sup> was used to determine <italic>K</italic><sub>i</sub> using <xref rid="eq4" ref-type="disp-formula">eq <xref rid="eq4" ref-type="disp-formula">4</xref></xref>:<disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_m004" position="anchor"/><label>4</label></disp-formula></p></sec></sec><sec id="sec2.7"><title>Crystallization and Structure Determination</title><p>IMP-1 and
L1 were crystallized as previously described.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref51">51</xref></sup> Inhibitor-bound structures were obtained by soaking crystals in
the compound (2.5 mM) and cryoprotectant (reservoir solution with
25% glycerol) for 5 min (IMP-1 with <bold>3a</bold>) or 15 min (L1
with <bold>3a</bold> and <bold>3b</bold>). Crystals were subsequently
flash-frozen in liquid nitrogen for data collection. Longer soaks
for IMP-1 crystals resulted in severe deterioration of the crystal,
while shorter soaks for L1 resulted in active sites that did not contain
difference density suggestive of ligand binding. Data sets were collected
at 100 K on beamline I02 (Diamond Light Source), integrated in XDS,<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> and scaled and merged using Aimless.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Phases were calculated by molecular replacement
in Phaser<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> using Protein Data Bank (PDB)
entries 1SML(<xref ref-type="bibr" rid="ref51">51</xref>) and 5EV6(<xref ref-type="bibr" rid="ref18">18</xref>) as search
models for L1 and IMP-1, respectively. Structures were completed by
iterative rounds of manual model building in Coot<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> and refinement in Phenix.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> Ligand
structures and geometric restraints were calculated with Phenix eLBOW.
Structure validation was assisted by Molprobity<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> and Phenix. Figures were prepared using PyMol (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.pymol.org">www.pymol.org</uri>).</p></sec><sec id="sec2.8"><title>Protein Structure
Accession Numbers</title><p>Coordinates and
structure factors have been deposited in the PDB under the following
accession codes: IMP-1:<bold>3a</bold>, 5HH4; L1:<bold>3a</bold>, 5HH5; L1:<bold>3b</bold>, 5HH6.</p></sec></sec><sec id="sec3"><title>Results
and Discussion</title><sec id="sec3.1"><title>PMPCs are <italic>in Vitro</italic> Inhibitors
of B1 and B3
MBLs</title><p>Numerous classes of chelating agents, including 2-picolinic
acid [<bold>1</bold> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>)] and its derivatives, have been evaluated as potential MBL
inhibitors.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> In particular, dicarboxylate
derivatives of pyridine have been reported to exhibit significant
inhibitory activity against some MBLs.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> These include dipicolinic acid (DPA, 2,6-pyridine dicarboxylate),
which can inhibit the class B1 MBLs CcrA and IMP-1 and the class B3
MBL L1,<sup><xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref62">62</xref></sup> and 2,4-pyridine dicarboxylate, which inhibits
the class B2 MBL CphA.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> However, DPA is
a zinc chelator<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and has been shown to
remove one zinc ion slowly from the active site of IMP-1 at high concentrations.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> In addition, a DPA derivative has been shown
to be a submicromolar inhibitor of the B1 enzyme NDM-1.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> Although the exact binding mode is not known,
this compound did not strip NDM-1 of its metal ions but bound to the
active site. We have previously synthesized phosphonate-based derivatives
of <bold>1</bold> [6-phosphonomethylpyridine-2-carboxylates (PMPCs)]
and showed them to be weak inhibitors (IC<sub>50</sub>&#x02019;s of
60&#x02013;130 &#x003bc;M) of bacterial fructose-1,6-bisphosphate aldolase,
an enzyme that uses a single zinc ion in its active site.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Here we test a selection of these derivatives,
alongside some newly synthesized molecules (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>), as potential inhibitors of the clinically
relevant class B1 MBLs VIM-2, NDM-1, and IMP-1 and the class B3 MBL
L1 (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). We also
tested <bold>1</bold> and 6-methyl-2-picolinic acid (<bold>2</bold>; <bold>1</bold> with a methyl group at C6 of the pyridine ring),
with both having a weak inhibitory effect toward the MBLs tested (IC<sub>50</sub>&#x02019;s from 32.2 to &#x0003e;100 &#x003bc;M), indicating that
a
single Zn-coordinating group on the pyridine ring cannot efficiently
inhibit MBLs. The addition of a phosphonomethyl group on C6 of <bold>1</bold> (<bold>3a</bold>, PMPC-1) results in significant potency
against all MBLs tested (IC<sub>50</sub>&#x02019;s of 0.374&#x02013;3.88
&#x003bc;M) with a submicromolar IC<sub>50</sub> against the B1 MBL
NDM-1. The addition of a hydroxyl group on the carbon of the phosphonomethyl
group (<bold>3b</bold>, PMPC-2) had little effect compared to <bold>3a</bold> as IC<sub>50</sub> values were similar toward all MBLs
tested. <bold>3c</bold> (PMPC-3) was synthesized with an additional
large hydrophobic substituent on the phosphonomethyl group, with the
aim of exploiting conserved hydrophobic areas within the active sites
of B1 MBLs, particularly flexible loop L3 (residues 60&#x02013;66)
previously implicated in substrate/inhibitor interactions.<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> Compared to <bold>3a</bold>, <bold>3c</bold> exhibits slightly improved potency of approximately 1.2&#x02013;2.8-fold
against NDM-1, VIM-2, and IMP-1 (IC<sub>50</sub>&#x02019;s of 0.306&#x02013;2.91
&#x003bc;M) and similar potency against L1 (&#x0223c;0.9-fold). The carboxylate
at position 2 of the pyridine ring, however, is essential as removal
of this group (<bold>4</bold>) essentially abolishes MBL inhibitory
activity of the PMPCs. The PMPC phosphonate compounds <bold>3a&#x02013;3c</bold> are therefore all low micromolar inhibitors of both B1 and B3 MBLs.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>IC<sub>50</sub> Values for PMPCs against
Representative MBLs with Nitrocefin as a Substrate</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th colspan="4" align="center" char=".">IC<sub>50</sub> (&#x003bc;M)<hr/></th></tr><tr><th style="border:none;" align="center">inhibitor</th><th style="border:none;" align="center" char=".">VIM-2</th><th style="border:none;" align="center" char=".">NDM-1</th><th style="border:none;" align="center" char=".">IMP-1</th><th style="border:none;" align="center" char=".">L1</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">32.2</td><td style="border:none;" align="char" char=".">&#x0003e;100</td><td style="border:none;" align="char" char=".">&#x0003e;100</td><td style="border:none;" align="char" char=".">&#x0003e;100</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">&#x0003e;100</td><td style="border:none;" align="char" char=".">&#x0003e;100</td><td style="border:none;" align="char" char=".">&#x0003e;100</td><td style="border:none;" align="char" char=".">&#x0003e;100</td></tr><tr><td style="border:none;" align="left"><bold>3a</bold></td><td style="border:none;" align="char" char=".">1.29</td><td style="border:none;" align="char" char=".">0.374</td><td style="border:none;" align="char" char=".">3.88</td><td style="border:none;" align="char" char=".">1.48</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char=".">1.90</td><td style="border:none;" align="char" char=".">0.322</td><td style="border:none;" align="char" char=".">7.20</td><td style="border:none;" align="char" char=".">2.05</td></tr><tr><td style="border:none;" align="left"><bold>3c</bold></td><td style="border:none;" align="char" char=".">0.464</td><td style="border:none;" align="char" char=".">0.306</td><td style="border:none;" align="char" char=".">2.91</td><td style="border:none;" align="char" char=".">1.57</td></tr><tr><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">171</td><td style="border:none;" align="char" char=".">&#x0003e;1000</td><td style="border:none;" align="char" char=".">&#x0003e;100</td><td style="border:none;" align="char" char=".">&#x0003e;1000</td></tr></tbody></table></table-wrap><p>Identification of phosphonates
as effective MBL inhibitors motivated
more detailed kinetic studies aimed at probing the mode of inhibition
for the PMPCs. Notably, nitrocefin hydrolysis progress curves, obtained
without premixing of enzyme and inhibitor, for both B1 (IMP-1, NDM-1,
and VIM-2) and B3 (L1) MBLs (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figures S1&#x02013;S3</ext-link>) showed burst kinetics. This is consistent with observations that
reliable IC<sub>50</sub> values could be obtained only when the enzyme
and the inhibitor were subjected to a 10 min preincubation before
addition of the substrate. These data strongly indicate that phosphonate
inhibition of MBLs does not follow a simple competitive model but
that activity instead involves a time-dependent component. This behavior
was apparent in the progress curves for inhibition by compounds <bold>3a</bold> (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S1</ext-link>), <bold>3b</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S2</ext-link>), and <bold>3c</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S3</ext-link>); in all cases, these could be fitted
using <xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula">2</xref></xref> as detailed
in <xref rid="sec2" ref-type="other">Materials and Methods</xref>.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p><bold>3a</bold> inhibits
MBLs by a time-dependent mechanism. Progress
curves and secondary linear plots (insets) for <bold>3a</bold> inhibition
of nitrocefin hydrolysis by IMP-1, L1, NDM-1, and VIM-2. The curve
fitting procedure is described in the text. The error bars in the
progress curves represent three technical replicates.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0002" id="gr2" position="float"/></fig><p>Time-dependent or slow-binding inhibition<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> can be described by two alternative mechanisms
(<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>). In the
simpler case, the
inhibitory EI complex forms in a single, slow step, whereas in the
more general case, the initial inhibitory complex EI isomerizes slowly
to form the steady-state enzyme&#x02013;inhibitor complex EI*. These
two models can be distinguished by replots of the derived first-order
rate constant, <italic>k</italic><sub>obs</sub>, against inhibitor
concentration [I]; in the single-step case, <italic>k</italic><sub>obs</sub> increases linearly with [I], and in the two-step model,
dependence is instead hyperbolic. In all cases, these secondary plots
show the linear dependence of <italic>k</italic><sub>obs</sub> on
[I], leading us to conclude that formation of the inhibitory PMPC:MBL
complex occurs in a single step.</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Possible Mechanisms for Slow-Binding
Inhibition</title><p id="sch1-fn1">In the simpler case (left,
observed here), the inhibitory EI complex forms by a single, slow
step. In the more general case (right), the initial inhibitory EI
complex isomerizes slowly to form the steady-state inhibitory complex
EI*.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0006" id="gr6" position="float"/></fig><p>Using this treatment, we determined inhibition
constants (<italic>K</italic><sub>i</sub>) for phosphonates <bold>3a&#x02013;3c</bold> against VIM-2, NDM-1, IMP-1, and L1. As with
the IC<sub>50</sub> data, <italic>K</italic><sub>i</sub> values (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>) indicate the compounds
are similarly potent,
showing a particularly dramatic effect against NDM-1 (<italic>K</italic><sub>i</sub> = 34&#x02013;74 nM). As described above, <bold>3a&#x02013;3c</bold> all demonstrated a slow-binding competitive inhibition profile against
all MBLs, with a slow &#x0201c;on&#x0201d; rate and even slower &#x0201c;off&#x0201d;
rate (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S1</ext-link>) but no isomerization step.
Inspection of the rate constants in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S1</ext-link> shows a range of values for the on rate (<italic>k</italic><sub>0</sub>) between 0.08 and 6.4 s<sup>&#x02013;1</sup>, i.e., almost
2 orders of magnitude, while the off rate (<italic>k</italic><sub>&#x02013;0</sub>) exhibits less variation. Of the four enzymes tested,
values of <italic>k</italic><sub>0</sub> are consistently highest
for NDM-1, and consistently lowest for IMP-1, which also exhibits
the lowest <italic>k</italic><sub>&#x02013;0</sub> values. Comparison
of values for the different compounds reveals that PMPC <bold>3c</bold>, which incorporates relatively hydrophobic functionalities, has
on rate constants (<italic>k</italic><sub>0</sub>) for the B1 MBLs
(IMP-1, NDM-1, and VIM-2) that are higher than those of the other
PMPCs, although no difference is observed for the B3 L1 enzyme.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Inhibition Constants for PMPCs against
MBLs</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th colspan="4" align="center" char="&#x000b1;"><italic>K</italic><sub>i</sub> (&#x003bc;M)<hr/></th></tr><tr><th style="border:none;" align="center">inhibitor</th><th style="border:none;" align="center" char="&#x000b1;">VIM-2</th><th style="border:none;" align="center" char="&#x000b1;">NDM-1</th><th style="border:none;" align="center" char="&#x000b1;">IMP-1</th><th style="border:none;" align="center" char="&#x000b1;">L1</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>3a</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.54&#x000a0;&#x000b1;&#x000a0;0.05</td><td style="border:none;" align="char" char="&#x000b1;">0.07&#x000a0;&#x000b1;&#x000a0;0.01</td><td style="border:none;" align="char" char="&#x000b1;">1.1&#x000a0;&#x000b1;&#x000a0;0.2</td><td style="border:none;" align="char" char="&#x000b1;">0.5&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td style="border:none;" align="left"><bold>3b</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.61&#x000a0;&#x000b1;&#x000a0;0.04</td><td style="border:none;" align="char" char="&#x000b1;">0.078&#x000a0;&#x000b1;&#x000a0;0.008</td><td style="border:none;" align="char" char="&#x000b1;">1.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td style="border:none;" align="char" char="&#x000b1;">0.4&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td style="border:none;" align="left"><bold>3c</bold></td><td style="border:none;" align="char" char="&#x000b1;">0.038&#x000a0;&#x000b1;&#x000a0;0.009</td><td style="border:none;" align="char" char="&#x000b1;">0.034&#x000a0;&#x000b1;&#x000a0;0.006</td><td style="border:none;" align="char" char="&#x000b1;">0.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td style="border:none;" align="char" char="&#x000b1;">0.4&#x000a0;&#x000b1;&#x000a0;0.1</td></tr></tbody></table></table-wrap><p>Previous descriptions
of slow-binding inhibition of MBLs, e.g.,
of IMP-1 by certain thiols,<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> or of the
model MBL <italic>Bacillus cereus</italic> BcII by thiols formed on
opening of the dihydrothiazine ring of cephalosporins,<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> propose that slow binding is likely due to the
involvement of an isomerization step in formation of the inhibitory
complex EI* (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>). An alternative explanation is necessary to account for the single-step
pathway observed here. In this context, we note recent molecular dynamics
simulations<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> suggesting that slow binding
may arise, at least for some inhibitors, because of favorable interactions
of the inhibitor with transient enzyme-bound water molecules present
on initial association that are removed by stepwise dehydration to
generate the final inhibitory complex. It is reasonable to suggest
that such mechanisms may be involved in the slow-binding inhibition
of MBLs by PMPCs, particularly given the polar character of these
compounds. This could also explain why, unlike what is observed for
the B1 MBLs tested, the on rate (<italic>k</italic><sub>0</sub>) for
PMPC <bold>3c</bold> inhibition of L1 does not differ substantially
from those observed for <bold>3a</bold> and <bold>3b</bold>. One consequence
of the structural differences between the B1 and B3 enzymes may be
differing spatial distributions of water molecules within and near
the active sites, requiring a different pathway to be taken from the
initial, hydrated, complex to the stable, inhibitory complex analogous
to that formed with the B1 enzymes.</p><p>The off rate constants (<italic>k</italic><sub>&#x02013;0</sub>)
in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S1</ext-link> also provide some insight into
the residency times of PMPC inhibitors at the MBL-binding sites, which
may be calculated as dissociative half-lives (<italic>t</italic><sub>1/2</sub> = 2/<italic>k</italic><sub>&#x02013;0</sub>) and are summarized
in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S2</ext-link>. Values range from 6 min (complex
of <bold>3b</bold> and VIM-2) to 25 min (<bold>3c</bold> and IMP-1).
Recent work<sup><xref ref-type="bibr" rid="ref70">70</xref>&#x02212;<xref ref-type="bibr" rid="ref73">73</xref></sup> highlights the importance of assessing kinetic data on drug&#x02013;target
residence time, as well as equilibrium binding constants, in analyzing
structure&#x02013;activity relationship data during lead optimization
of drug candidates. A long residency time can extend the duration
of drug effects <italic>in vivo</italic> and enhance selectivity if
the residency time exceeds those for related off-target enzymes. Such
considerations will play an important role in our future efforts to
advance the PMPCs toward compounds with clinical potential.</p><p>In addition to the distinctive slow-binding behavior observed here,
the kinetics observed with the PMPCs also differ from those observed
for the natural product aspergillomarasmine A that attenuates NDM-1
and VIM-2 activity (but not that of IMP-7 or the B3 enzyme AIM) by
removing both zinc ions.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> Notably, these
compounds have a potency against a range of MBL targets that is greater
than that of captopril<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> and show potency
similar to, and sometimes better than, those of other thiol-based
compounds such as mercaptophosphonates,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> with IC<sub>50</sub> values ranging from 0.3 to 7.2 &#x003bc;M across
all MBL/inhibitor combinations tested.</p></sec><sec id="sec3.2"><title>PMPCs Enhance Meropenem
Antibacterial Activity against MBL-Producing
Bacteria</title><p>We next tested the ability of the simplest of our
synthesized phosphonate compounds, <bold>3a</bold>, to enhance the
antibacterial activity of Meropenem against bacterial strains producing
the most clinically relevant subclass B1 MBLs from introduced broad
host range plasmids or clinical isolates. The Meropenem MIC was first
measured using bacteria expressing the cloned MBLs IMP-1 (<italic>E. coli</italic>), VIM-1 [the most prevalent VIM MBL subtype in Enterobactaeriaceae<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> (sequence 90.6% identical to that of VIM-2), <italic>E. coli</italic>], and NDM-1 (<italic>E. coli</italic>, <italic>K.
pneumoniae</italic>, <italic>C. freundii</italic>, and <italic>En.
aerogenes</italic>) (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). In all cases, other than that of VIM-1 expressed in laboratory <italic>E. coli</italic> strain MG1655, MBL expression conferred resistance
to Meropenem as judged by CLSI (resistance is defined by MICs of &#x02265;4
mg/L for Enterobacteriacae and &#x02265;8 mg/L for <italic>P. aeruginosa</italic>) or EUCAST (resistance MICs of &#x0003e;8 mg/L for Enterobacteriacae
and <italic>P. aeruginosa</italic>) breakpoints.<sup><xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref75">75</xref></sup> Co-administration
with <bold>3a</bold> reduced Meropenem MICs into the susceptible range
against all strains except <italic>E. coli</italic> MG1655 expressing
NDM-1 (MIC = 8 mg/L), although this required 100 mg/L <bold>3a</bold> to achieve. In all cases, at 100 mg/L <bold>3a</bold>, the Meropenem
MIC was reduced by at least 16-fold. Against <italic>K. pneumoniae</italic>, <italic>C. freundii</italic>, and <italic>En. aerogenes</italic> expressing NDM-1, MICs were enhanced to 4, 2, and 1 mg/L, respectively,
but not restored to Meropenem MICs against non-MBL-producing strains
(&#x02264;0.25,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> 0.06, and 0.06 mg/L,<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> respectively). For wild-type clinical isolates
(<italic>P. putida</italic>, <italic>P. aeruginosa</italic>, <italic>S. maltophilia</italic>, one <italic>K. pneumoniae</italic>, and
one <italic>E. coli</italic>) (<xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>), a similar trend was observed, with some reduction
in Meropenem MICs against all nine strains tested. There was a &#x0003e;4-fold
reduction in Meropenem MIC against eight of the nine strains tested
at 128 mg/L <bold>3a</bold>, with five of nine strains reverting from
Meropenem resistance to susceptibility (EUCAST definition Meropenem
MICs of &#x02264;2 mg/L) at the same concentration of <bold>3a</bold>. In the case of the NDM-1-producing <italic>K. pneumoniae</italic> clinical isolate in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>, a meaningful comparison of the potency of <bold>3a</bold> and AMA is possible because this same strain has been employed in
a study of the effect of AMA on Meropenem MIC.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The MIC for Meropenem was reduced to 0.25 mg/L in the presence
of 16 mg/L AMA and to &#x0003c;0.125 mg/L in the presence of 32 mg/L AMA.
Here, the MIC for Meropenem was found to be reduced to 0.25 mg/L in
the presence of 32 mg/L <bold>3a</bold> and to &#x0003c;0.125 mg/L at 64
mg/L inhibitor. Notably, <bold>3a</bold> enhanced Meropenem activity
against an <italic>E. coli</italic> strain (UWB75) carrying both an
SBL (CTX-M-15, which lacks meaningful carbapenemase activity) and
the NDM-1 MBL (4-fold reduction at 32 mg/L inhibitor; &#x0003e;512-fold
reduction,
from 128 to &#x0003c;0.25 mg/L, at 128 mg/L).</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Potentiation
of Meropenem Activity
against Recombinant B1 MBL-Producing Bacteria by PMPCs</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th colspan="4" align="center" char=".">Meropenem
MIC (mg&#x02009;L<sup>&#x02013;1</sup>)<hr/></th></tr><tr><th style="border:none;" align="center">strain</th><th style="border:none;" align="center">MBL<xref rid="t3fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center" char=".">in the absence of inhibitor</th><th style="border:none;" align="center" char=".">in the presence of 10 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the presence of of 50 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the
presence of 100 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>E. coli</italic> MG1655</td><td style="border:none;" align="left">vector only</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic> MG1655</td><td style="border:none;" align="left">IMP-1</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic> MG1655</td><td style="border:none;" align="left">VIM-1</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic> MG1655</td><td style="border:none;" align="left">NDM-1</td><td style="border:none;" align="char" char=".">&#x0003e;256</td><td style="border:none;" align="char" char=".">&#x0003e;256</td><td style="border:none;" align="char" char=".">128</td><td style="border:none;" align="char" char=".">8</td></tr><tr><td style="border:none;" align="left"><italic>K. pneumoniae</italic> Ecl8</td><td style="border:none;" align="left">NDM-1</td><td style="border:none;" align="char" char=".">&#x0003e;256</td><td style="border:none;" align="char" char=".">&#x0003e;256</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">4</td></tr><tr><td style="border:none;" align="left"><italic>C. freundii</italic> D571</td><td style="border:none;" align="left">NDM-1</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left"><italic>En. aerogenes</italic> 15-8358A</td><td style="border:none;" align="left">NDM-1</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">1</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>MBL expressed from its native promoter,
encoded on the pSU18 vector.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Potentiation of Meropenem Activity
against MBL-Producing Clinical Strains by <bold>3a</bold></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th colspan="7" align="center" char=".">Meropenem
MIC (mg&#x02009;L<sup>&#x02013;1</sup>)<hr/></th></tr><tr><th style="border:none;" align="center">strain</th><th style="border:none;" align="center">resistance determinant (MBL/SBL)</th><th style="border:none;" align="center" char=".">in the absence of inhibitor</th><th style="border:none;" align="center" char=".">in the presence of 4 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the presence of
8 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the presence of 16 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the presence of
32 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the presence of 64 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th><th style="border:none;" align="center" char=".">in the presence of
128 mg&#x02009;L<sup>&#x02013;1</sup><bold>3a</bold></th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic> UWB41</td><td style="border:none;" align="left">VIM-2</td><td style="border:none;" align="char" char=".">128</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0.5</td></tr><tr><td style="border:none;" align="left"><italic>P. putida</italic> #UWB24</td><td style="border:none;" align="left">VIM-2</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic> UWB75</td><td style="border:none;" align="left">NDM-1/CTX-M-15</td><td style="border:none;" align="char" char=".">128</td><td style="border:none;" align="char" char=".">128</td><td style="border:none;" align="char" char=".">128</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">&#x0003c;0.25</td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic> UWB78</td><td style="border:none;" align="left">VIM-2</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">64</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">4</td></tr><tr><td style="border:none;" align="left"><italic>S. maltophilia</italic> K279a</td><td style="border:none;" align="left">L1, L2</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">4</td></tr><tr><td style="border:none;" align="left"><italic>S. maltophilia</italic> Kami32</td><td style="border:none;" align="left">L1,
L2</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">8</td></tr><tr><td style="border:none;" align="left"><italic>S. maltophilia</italic> JKWZP</td><td style="border:none;" align="left">L1, L2</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">8</td></tr><tr><td style="border:none;" align="left"><italic>K. pneumoniae</italic> UWB116</td><td style="border:none;" align="left">NDM-1</td><td style="border:none;" align="char" char=".">32</td><td style="border:none;" align="char" char=".">16</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">0.25</td><td style="border:none;" align="char" char=".">&#x0003c;0.125</td><td style="border:none;" align="char" char=".">&#x0003c;0.125</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic> UWB93</td><td style="border:none;" align="left">IMP-1/CTX-M-15</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">0.5</td><td style="border:none;" align="char" char=".">0.25</td></tr></tbody></table></table-wrap><p>Compounds <bold>3b</bold> and <bold>3c</bold> were next tested
against a subset of clinical MBL-producing strains in a preliminary
assessment of the effects of substitutions upon biological activity
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S3</ext-link>). Importantly, in all cases,
we observed reductions in Meropenem MICs in the presence of PMPCs,
although the effects were variable. The modifications in <bold>3b</bold> and <bold>3c</bold> exerted an effect similar to that of <bold>3a</bold> upon the potency of Meropenem combinations against <italic>E. coli</italic> UWB93 and <italic>K. pneumoniae</italic> UWB116. However, against <italic>E. coli</italic> UWB75 (the isolate for which the Meropenem MIC was
highest), the effectiveness of both <bold>3b</bold> and <bold>3c</bold> was reduced, with <bold>3c</bold> unable to restore Meropenem susceptibility
at 128 mg/L. <bold>3b</bold> and <bold>3c</bold> were also less effective
against the two <italic>Pseudomonas</italic> spp. strains for which,
unlike <bold>3a</bold>, neither compound could restore Meropenem susceptibility,
even at 128 mg/L. Despite the difference in size, <bold>3b</bold> and <bold>3c</bold> behaved identically toward <italic>P. putida</italic> isolate
UWB24, whereas for <italic>P. aeruginosa</italic> UWB78, <bold>3c</bold> appeared to be less effective than <bold>3b</bold>, although the
effects were subtle (4-fold difference in Meropenem MIC at the highest
concentration tested). These data indicate that modifications to the
PMPC scaffold affect, but do not abolish, activity in bacterial growth
assays. Indeed, the potency against Enterobacteriaceae (a group of
pathogens in which MBL-mediated carbapenem resistance is particularly
concerning) was in many cases tolerant of additions to the PMPCs.</p><p>We also tested the activity of <bold>3a</bold> against <italic>S.
maltophilia</italic>, a notoriously impermeable pathogen of compromised
individuals and a growing problem in cystic fibrosis patients.<sup><xref ref-type="bibr" rid="ref77">77</xref>,<xref ref-type="bibr" rid="ref78">78</xref></sup> Compared to those of the <italic>E. coli</italic>, <italic>K. pneumoniae</italic>, and <italic>Pseudomonas</italic> spp. isolates, the activity of <bold>3a</bold> was reduced (<xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>). Nevertheless, <bold>3a</bold> was able to potentiate Meropenem
activity (4-fold reduction in MIC values) against the clinical multidrug
resistant <italic>S. maltophilia</italic> bloodstream isolate K279a.
To determine whether PMPC potency is influenced by efflux, we measured
MICs in a K279a derivative overexpressing the resistance nodulation
division (RND) efflux pump SmeYZ (<italic>S. maltophilia</italic> K
ami32), and an additional knockout strain lacking the RND pumps SmeJ/K/W/Z/P
(<italic>S. maltophilia</italic> JKWZP). In the presence of <bold>3a</bold>, Meropenem MICs were reduced by a single 2-fold dilution
against overexpression strain K ami32 and 4-fold against the JKWZP
efflux pump knockout strain, suggesting that PMPCs are only slightly
affected by efflux in <italic>S. maltophilia</italic>.</p><p>Taken
together, these experiments indicate that PMPCs, in particular <bold>3a</bold>, are able to inhibit a range of MBLs expressed in the periplasm
and enhance &#x003b2;-lactam activity against a wide range of Gram-negative
bacteria. While relatively high PMPC concentrations (32&#x02013;128
mg/L) were required to restore Meropenem susceptibility (which was
not always achieved), activity was observed against a range of target
species, including nonfermenters, and was relatively unaffected by
alterations to known efflux systems. These data indicate that while
compounds in this initial series may not show optimal penetration
of the Gram-negative outer membrane, some entry into the periplasm
is occurring even in problematic species such as <italic>P. aeruginosa</italic> and <italic>S. maltophilia</italic>. This supports our contention
that these initial examples of the PMPC scaffold can be viable lead
structures for further optimization. Importantly, we consider this
to remain valid despite the presence of multiple ionizable groups
that might be expected to create complications with respect to pharmacokinetics
or drug delivery. The literature p<italic>K</italic><sub>a</sub> values
of approximately 2.5 and 8 for the first and second ionizations of
phosphonates,<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> respectively, and of 1.0
for 2-picolinic acid<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> lead us to expect
that at physiological pH the PMPCs will exist largely in a dianionic
form. Given the ample precedents for dianionic &#x003b2;-lactams (e.g.,
carbenicillin or ticarcillin<sup><xref ref-type="bibr" rid="ref81">81</xref></sup>) being suitable
for clinical use as antibiotics for Gram-negative bacteria, including <italic>P. aeruginosa</italic>, we do not expect the ionization state of
these inhibitors to be necessarily problematic.</p><p>Although a previous
study showed <bold>3a</bold> to be nontoxic
to immortal African green monkey kidney cells (BL-C-1),<sup><xref ref-type="bibr" rid="ref82">82</xref></sup> due to the relatively high concentrations (up
to 100 mg/L) of the inhibitor required for significant reduction in
MIC, we tested the toxicity of <bold>3a</bold> against Caco-2 (human
epithelial), HEPG2 (human liver), and H4IIE (rat hepatoma) cells at
higher concentrations. These data show <bold>3a</bold> does not affect
the metabolic activity, membrane integrity, or lysosome integrity
of these cell lines until concentrations reach values significantly
higher than those at which MIC reductions are observed, with EC<sub>50</sub> values of &#x02265;242 mg/L (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S4</ext-link>).</p></sec><sec id="sec3.3"><title>Determination of the Structure of MBLs Complexed with Phosphonate
Compounds</title><p>To understand the mechanism of MBL inhibition by
PMPCs, we have obtained crystal structures of the B1 MBL IMP-1 (an
enzyme found on plasmids in a range of Gram-negative bacterial pathogens,
particularly <italic>P. aeruginosa</italic>) in complex with <bold>3a</bold> (2.0 &#x000c5; resolution) and the B3 L1 enzyme (encoded on
the chromosome of <italic>S. maltophilia</italic>) in complex with
both <bold>3a</bold> (1.80 &#x000c5;) and <bold>3b</bold> (1.80 &#x000c5;)
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Table S5</ext-link>). IMP-1 crystallized in space
group <italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with
four molecules in the asymmetric unit (ASU), as previously described
(PDB entry 5EV6(<xref ref-type="bibr" rid="ref18">18</xref>)). <bold>3a</bold> could be modeled
into well-defined difference electron density (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a) in two of the four chains in the ASU,
with full occupancies and <italic>B</italic>-factors 1.3 times above
that of the protein main chain (chain A validation statistics, RSCC
of 0.96, RSR of 0.12, and LLDF of 1.95). L1 crystallized in space
group <italic>P</italic>6<sub>4</sub>22, as previously described,<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> with one molecule in the ASU. Difference electron
density consistent with <bold>3a</bold> or <bold>3b</bold> (panel
b or c of <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>,
respectively) was observed in the active sites of the two crystal
structures, and ligands were refined at full or 0.84 occupancy to <italic>B</italic>-factors 1.9 and 1.7 times above that of the protein main
chain, respectively (RSCC values of 0.96 and 0.93, RSR values of 0.16
and 0.14, and LLDF values of 3.94 and 5.64, respectively).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Binding of
PMPC inhibitors to MBL active sites. Close-up of the
active sites of MBL:PMPC complexes. Zinc ions and the nucleophilic
water/hydroxide (gray and red spheres, respectively) are labeled.
Zinc ligands are shown as sticks. The <italic>F</italic><sub>0</sub> &#x02013; <italic>F</italic><sub>c</sub> density (green, contoured
at 3&#x003c3;) is calculated from the final model with the ligand (sticks)
omitted. (a) B1 IMP-1 complexed with <bold>3a</bold>. (b) B3 L1 complexed
with <bold>3a</bold>. (c) B3 L1 complexed with <bold>3b</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0003" id="gr3" position="float"/></fig></sec><sec id="sec3.4"><title>Mode of Binding of PMPC
to the B1 MBL IMP-1 Dizinc Center</title><p><bold>3a</bold> binds to
the dizinc active site of IMP-1 but does
not displace the nucleophilic hydroxide [Wat1 (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a)]. <bold>3a</bold> adopts the same conformation
in chains A and B, interacting with the Zn2 ion, nucleophilic hydroxide,
and residues on the protein main chain (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a), but binding does not result in global
changes in conformation in comparison to the uncomplexed enzyme structure
(PDB entry 5EV6,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> RMSD = 0.21 &#x000c5;, chain A, over
218 C&#x003b1; residues). The inhibitor carboxylate group and pyridine
nitrogen atom both interact with the Zn2 site, at distances of 2.30
and 2.69 &#x000c5; (chain A measurements throughout, unless otherwise
stated; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S4</ext-link> for a schematic comparison
of binding in chains A and B), respectively, resulting in a zinc ion
with six ligands in a distorted octahedral geometry, in contrast to
Zn2 in uncomplexed IMP-1 that has a distorted trigonal bipyramidal
geometry. The carboxylate also interacts with Lys224 on the protein
main chain (2.70 &#x000c5;), and binding is further stabilized by the
proximity of a hydrophobic pocket [Val61, Val67, Trp64, and Phe87
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S5</ext-link>)]. A weak T-shaped interaction<sup><xref ref-type="bibr" rid="ref83">83</xref></sup> of the pyridine ring with the face of the indole
ring of Trp64 on the flexible loop L3 (pyridine C4&#x02013;indole C3
distances of 3.72 and 3.94 &#x000c5; in chains A and B, respectively)
is also observed. The pyridine nitrogen is also positioned close to
the zinc-bridging hydroxide (Wat1 in <xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig5" ref-type="fig">5</xref>; 2.9 &#x000c5;),
with the torsion about the phosphonate C&#x02013;P bond approximately
90&#x000b0; relative to the plane of the pyridine ring. Surprisingly,
the phosphonate makes limited interactions with the active site and
is too distant from the zinc ions for productive interactions (the
closest O atom is 3.89 &#x000c5; from Zn1 and 4.35 &#x000c5; from Zn2),
instead forming hydrogen bonds with the bridging water/hydroxide (Wat1)
(2.58 &#x000c5;) and the side chain of Ser119 (3.26 &#x000c5;).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Mode of binding
of <bold>3a</bold> to B1 MBL IMP-1. PMPC and the
antibiotic are shown as sticks. Zn sites and nucleophilic waters/hydroxides
(Wat1) are labeled. (a) <bold>3a</bold> (blue sticks) bound to the
active site of IMP-1. Ligand interactions (distances labeled) and
zinc&#x02013;protein interactions are shown as yellow and gray dotted
lines, respectively. (b) Superposition of the IMP-1:<bold>3a</bold> complex (gray) with uncomplexed IMP-1 (green, PDB entry 5EV6). (c) Superposition
of the IMP-1:<bold>3a</bold> complex (gray) with the NDM-1:hydrolyzed
cephalexin complex (pink, PDB entry 5EV6). IMP-1 zinc ions are colored light gray
and NDM-1 zinc ions dark gray.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0004" id="gr4" position="float"/></fig><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Mode of binding of PMPCs to B3 MBL L1. Representations are as in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>. Interactions of
L1 with (a) <bold>3a</bold> and (b) <bold>3b</bold>. (c) Superposition
of the L1:<bold>3a</bold> complex (gray) with uncomplexed L1 (green).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2017-01299s_0005" id="gr5" position="float"/></fig><p>In addition to forming interactions
with the bridging hydroxide,
the <bold>3a</bold>:IMP-1 complex contains an additional water molecule
associated with the inhibitor. This water molecule (blue WatA in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figures S4 and S6</ext-link>; <italic>B</italic>-factor
= 34 &#x000c5;<sup>2</sup>) is located on the same face of the pyridine
ring as the phosphonate group and is within H-bonding distance (2.63
&#x000c5;) of the phosphonate oxygen atom that interacts with the bridging
hydroxide. Furthermore, this WatA contacts the &#x003c0;-bond between
N and C2 of the pyridine ring (3.03 and 3.17 &#x000c5; to the pyridine
N and C2 atoms, respectively). This attraction may arise from the
somewhat electron deficient nature of this &#x003c0;-bond resulting
from interaction of the pyridine nitrogen with Zn2. WatA is also within
H-bonding distance of the bridging hydroxide (2.84 &#x000c5;) and relatively
close to Zn1 (3.21 &#x000c5;) as well as to two of its ligands, His118
and His196 (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S4</ext-link>). The presence
of WatA and the relatively extensive interactions made by WatA lead
us to speculate that the IMP-1-bound inhibitory species is the hydrated
form of <bold>3a</bold>. This may explain why PMPC inhibition does
not involve displacement of the bridging hydroxide (see below) as
the associated loss of WatA would be expected to be energetically
unfavorable.</p><p>In chains C and D, where electron density for bound
PMPC could
not be resolved, the active site zinc ions were refined with lower
occupancies (<sup>C</sup>Zn1, 0.94; <sup>C</sup>Zn2, 0.87; <sup>D</sup>Zn1, 0.51; <sup>D</sup>Zn2, 1.0), suggesting that exposure to <bold>3a</bold> may have depleted zinc content. This may be a reason for
the lack of observable inhibitor electron density in these active
sites. The potential for a carboxylate-containing pyridine to remove
zinc from the IMP-1 active site has been noted previously, as incubation
of IMP-1 with DPA resulted in Cys221 (Zn2 ligand) becoming more accessible
to chemical modification.<sup><xref ref-type="bibr" rid="ref84">84</xref></sup></p><p>In comparison
with those of uncomplexed IMP-1, there is little
change in either protein side chain or zinc positions (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>b). In particular, the flexible
loop L3 and the &#x003c0;-stacking Trp64 are in the same conformation,
most likely because of crystal contacts in the ASU.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Interactions of loop L3 residues with bound inhibitors
frequently feature in inhibitor complexes of B1 MBLs.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref65">65</xref>,<xref ref-type="bibr" rid="ref85">85</xref></sup> The Zn1&#x02013;Zn2 separation is similar (3.54 &#x000c5; in IMP-1:<bold>3a</bold> and 3.42 &#x000c5; in uncomplexed IMP-1), although there is
a slight (0.5 &#x000c5;) shift in the position of Zn2 that in the inhibitor
complex increases the distances to the Asp120 (1.98 &#x000c5; for uncomplexed,
2.16 &#x000c5; for <bold>3a</bold>-bound) and Cys221 (2.31 &#x000c5; for
uncomplexed, 2.42 &#x000c5; for <bold>3a</bold>-bound) ligands. There
is a more significant (&#x0223c;1 &#x000c5;) movement of the bridging
nucleophilic water/hydroxide compared to uncomplexed IMP-1. This causes
the water to be nearly equidistant between Zn1 and Zn2 (2.05 and 2.21
&#x000c5;, respectively), whereas in the uncomplexed enzyme, the nucleophilic
water/hydroxide is 1.87 and 2.43 &#x000c5; from Zn1 and Zn2, respectively.
Interaction of an MBL inhibitor with the nucleophilic hydroxide is
unusual and, to the best of our knowledge, has been observed only
once before, in the interaction of the <italic>B. fragilis</italic> B1 MBL CfiA with a tricyclic carboxylate.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup> Far more common are inhibitor-binding modes that involve displacement
of the bridging hydroxide.</p><p>Interactions made by <bold>3a</bold> also share some aspects of
binding of an antibiotic to B1 MBLs. As to date there is no available
crystal structure of IMP-1 bound to either an intact or a hydrolyzed
antibiotic, in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>c we show a superposition of the IMP-1:<bold>3a</bold> complex with
NDM-1 complexed with the hydrolyzed cephalosporin cephalexin (chain
B of PDB entry 4RL2(<xref ref-type="bibr" rid="ref20">20</xref>)). As in inhibitor binding, the carboxylate
of the cephalosporin dihydrothiazine ring interacts with both Zn2
and Lys224, while the &#x003b2;-lactam nitrogen also contacts Zn2 forming
a distorted (though face monocapped) octahedral geometry. Thus, <bold>3a</bold> binding replicates some aspects of interactions of B1 MBLs
with their &#x003b2;-lactam substrates. However, the two complexes differ
substantially in that the interactions involving the carboxylate group
of hydrolyzed antibiotic create a trigonal bipyrimidal geometry about
Zn1, in contrast to the regular tetrahedral geometry of Zn1 observed
in the IMP-1:<bold>3a</bold> complex.</p></sec><sec id="sec3.5"><title>Binding of PMPC to B3 L1
Defines a Structurally Distinct Mode
of Inhibition</title><p>Crystal structures of complexes of the B3 MBL
L1 with <bold>3a</bold> and <bold>3b</bold> reveal an unprecedented
mode of inhibitor binding (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>a,b). Surprisingly, despite our <italic>in vitro</italic> kinetic data (above) indicating a similar mode of inhibition of
both IMP-1 and L1, the phosphonate moiety of both compounds replaces
the zinc ion in the Zn2 site of L1, forming a monozinc enzyme in which
only the Zn1 site is occupied. The PMPC therefore does not strip the
L1 active site of both zinc ions, even at such high inhibitor concentrations,
indicating that the PMPC binds specifically to the MBL active site.
Removal of zinc from the Zn2 site has only previously been seen by
incubation of L1 with relatively high concentrations (10 mM) of EDTA.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> In the case presented here, zinc displacement
by <bold>3a</bold> results in tight interaction of the phosphonate
directly with components of the dizinc center of the MBL. In particular,
in the <bold>3a</bold> and <bold>3b</bold> complexes, there is a strong
interaction (1.80 &#x000c5;) of the phosphonate group with Zn1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S7</ext-link>). This is notably tighter than the
contacts with the three Zn1 His ligands (&#x0223c;2.1 &#x000c5;). The
phosphonate also makes multiple interactions with the amino acid side
chains that normally constitute the Zn2 site in L1: His121 (2.89 and
2.68 &#x000c5; for <bold>3a</bold> and <bold>3b</bold>, respectively),
Asp120 (2.35 and 2.34 &#x000c5; for <bold>3a</bold> and <bold>3b</bold>, respectively), and His263 (2.68 and 2.56 &#x000c5; for <bold>3a</bold> and <bold>3b</bold>, respectively). Comparison of the <bold>3a</bold> and <bold>3b</bold> structures shows the hydroxyl group of the <bold>3b</bold> phosphonate to be uninvolved in binding, although, notably,
the high quality of the observed electron density makes it clear that
a single enantiomeric form of the inhibitor (the <italic>S</italic>-isomer rather than the <italic>R</italic>-isomer) is selectively
bound to the L1 active site, although the compound was synthesized
as a racemic mixture.</p><p>In comparison to uncomplexed L1 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>c shows a superposition
of the L1:<bold>3a</bold> complex, gray, with uncomplexed L1, green,
PDB entry 1SML), there is little change in the overall structure (C&#x003b1; RMSD
values of 0.233 and 0.234 &#x000c5; over 266 residues for L1:<bold>3a</bold> and L1:<bold>3b</bold>, respectively). However, binding of phosphonate
to the Zn2 site causes not only removal of the zinc ion but also significant
conformational changes within the active site. In particular, there
are &#x0223c;0.8 and &#x0223c;0.6 &#x000c5; movements of His263 and Asp120,
respectively, away from the active site. One of the phosphonate oxygen
atoms also replaces the nucleophilic water/hydroxide, which, in contrast,
is retained on binding of the hydrolyzed &#x003b2;-lactam moxalactam.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> Ser221 on the protein main chain, which stabilizes
the hydrolyzed substrate through interactions with the C3/C4 carboxylate
group,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> forms a dual conformation where
it interacts either with the PMPC phosphonate (3.11/3.12 &#x000c5;) or
carboxylate (2.92/2.58 &#x000c5;) groups. These two conformations could
be refined with similar occupancies (0.64/0.36 on <bold>3a</bold> binding
and 0.49/0.51 on <bold>3b</bold> binding). Ser223, which also forms
contacts with the carboxylate of the hydrolyzed substrate, interacts
here with the nitrogen of the pyridine ring (3.01/3.11 &#x000c5;). These
interactions suggest that, despite the very different mode of PMPC
binding compared to that of the hydrolyzed antibiotic,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> the two serine residues on the protein main
chain remain key to ligand stabilization within the active site.</p><p>The observation of different modes of PMPC binding in our crystal
structures, i.e., monozinc L1 and dizinc IMP-1 complexes, was unexpected.
However, the consistency between inhibition kinetics across the MBL
systems investigated leads us to conclude that, at least under the
conditions of our kinetic experiments, PMPCs are able to form an inhibitory
complex with dizinc L1 similar to that observed with IMP-1. In the
crystallization experiments, where the enzyme and inhibitor concentrations
are much greater, this may serve as a precursor to the observed more
stable complex from which the zinc ion has been lost from the L1 Zn2-binding
site. The fact that such a complex is not observed with IMP-1 may
then reflect differences in the metal-binding properties of the two
enzymes: whereas binding of zinc to L1 is proposed to be sequential,<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> with the Zn1 site being occupied first, binding
of zinc to IMP-1 is instead proposed to be positively cooperative.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup> As such, selective removal of zinc from the
Zn2 site, as observed in L1, would be disfavored in the IMP enzyme.
Furthermore, we observe favorable contacts made by PMPC inhibitors
with L1 side chain functionalities (e.g., the imidazole ring of His121
and the primary hydroxyl group of Ser221) that are not present in
the actives site of the B1 enzymes such as IMP (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">Figure S7</ext-link>), and that may additionally promote displacement
of the Zn2 ion by PMPCs.</p></sec></sec><sec id="sec4"><title>Conclusions</title><p>Phosphonate-based compounds
have been an underexplored and poorly
characterized area of MBL inhibitor design. Here we show they can
inhibit a wide range of MBLs, both <italic>in vitro</italic> and in
pathogenic Gram-negative bacteria, including nonfermenting organisms
that are frequently difficult to penetrate with small molecule agents.
Despite the potential for phosphonate compounds to act as zinc chelators,
we show crystallographically that they can bind specifically to the
active site of MBLs, either through a conventional (i.e., replicating
interactions of physiological substrates) mechanism of binding to
the Zn2 site in an otherwise largely unperturbed active site (B1 IMP-1)
or by the unprecedented mechanism of replacing Zn2 (B3 L1). Importantly,
despite this ability to remove a zinc ion from the dizinc active site
of L1, they are nontoxic to human cell lines at concentrations significantly
above levels required to potentiate antibiotic activity. Therefore,
unlike promising compounds such as aspergillomarasmine A (AMA), PMPCs
inhibit MBLs by binding to the active site, and not simply by chelating
the metal ions.</p><p>The structural information presented here will
also allow us to
identify routes to rational modification of the PMPCs to enhance their
affinity for the active sites of both B1 and B3 MBLs. In particular,
the mode of binding to IMP-1 reveals potential attachment sites on
the core PMPC structure (e.g., ortho to the carboxylate group) where
functionalities known to enhance the uptake of &#x003b2;-lactam antibiotics
(e.g., siderophores<sup><xref ref-type="bibr" rid="ref89">89</xref></sup>) might be introduced
without interfering with the favorable interactions of the inhibitors
with the MBL active site.</p><p>In summary, our data indicate that
phosphonates, in particular
2-picolinic acid derivatives that combine submicromolar potency against
multiple MBL targets with a simple scaffold amenable to further decoration,
can be further considered and developed as lead compounds for novel
MBL inhibitors.</p></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is
available free of charge on the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acs.biochem.7b01299">10.1021/acs.biochem.7b01299</ext-link>.<list id="silist" list-type="simple"><list-item><p>Figures S1&#x02013;S7,
Tables S1&#x02013;S5, and synthetic
procedures (includes Figures S8&#x02013;S29) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.7b01299/suppl_file/bi7b01299_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi7b01299_si_001.pdf"><caption><p>bi7b01299_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes3"><title>Author Contributions</title><p>P.H., C.A.T.,
A.P.K., G.L., V.J.G., L.M., A.Y.D., K.C., E.E.W., and F.Z. performed
the experiments. All authors analyzed data. P.H., C.A.T., G.L., M.B.A.,
N.C.B., S.S., J.S., and G.I.D. designed research. P.H., J.S., and
G.I.D. wrote the paper. P.H. and C.A.T. contributed equally to this
work.</p></notes><notes notes-type="funding-statement" id="notes-55"><p>This
work was
supported by grants from the U.K. Medical Research Council and Canadian
Institutes of Health Research (U.K.-Canada Team Grant G1100135 and
FRN114046) to J.S. and G.I.D., Canadian Institutes of Health Research
Operating Grant FRN106531 to G.I.D., a grant from the National Institute
of Allergy and Infectious Diseases of the U.S. National Institutes
of Health to J.S. (R01AI100560), and the Engineering and Physical
Sciences Research Council (EP/M027546/1) to M.B.A. and J.S. K.C. was
in receipt of a postgraduate scholarship from SENESCYT, Ecuador.</p></notes><notes notes-type="COI-statement" id="notes4"><p>The authors
declare no competing financial interest.</p></notes><notes notes-type="" id="notes-555"><title>Notes</title><p>Data
supporting this study are provided as
supplementary information accompanying this paper and crystal structures
are openly available from the Protein Data Bank (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</uri> 5hh4, 5hh5,
5hh6).</p></notes><ack><title>Acknowledgments</title><p>The authors
thank the Diamond Light Source for access
to beamline I02 (Proposal 12342) that contributed to the results presented
here and the staff of the Diamond macromolecular crystallography village
for their help. The authors thank Drs. J.-C. Jim&#x000e9;nez-Castellanos
and M. Alorabi for providing pSU18-containing strains and Drs. A.
McGeer, D. Pillai, and J. Pitout for providing clinical strains.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Bush</surname><given-names>K.</given-names></name> (<year>2013</year>) <article-title>Proliferation
and significance of clinically relevant beta-lactamases</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>1277</volume>, <fpage>84</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.12023</pub-id>.<pub-id pub-id-type="pmid">23346859</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Walsh</surname><given-names>T. R.</given-names></name> (<year>2010</year>) <article-title>Emerging
carbapenemases: a global perspective</article-title>. <source>Int. J.
Antimicrob. Agents</source>
<volume>36</volume> (<issue>Suppl. 3</issue>), <fpage>S8</fpage>&#x02013;<lpage>S14</lpage>. <pub-id pub-id-type="doi">10.1016/S0924-8579(10)70004-2</pub-id>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>van
Duin</surname><given-names>D.</given-names></name>; <name><surname>Kaye</surname><given-names>K. S.</given-names></name>; <name><surname>Neuner</surname><given-names>E. A.</given-names></name>; <name><surname>Bonomo</surname><given-names>R. A.</given-names></name> (<year>2013</year>) <article-title>Carbapenem-resistant
Enterobacteriaceae: a review of treatment and outcomes</article-title>. <source>Diagn. Microbiol. Infect. Dis.</source>
<volume>75</volume>, <fpage>115</fpage>&#x02013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2012.11.009</pub-id>.<pub-id pub-id-type="pmid">23290507</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Karsisiotis</surname><given-names>A. I.</given-names></name>; <name><surname>Damblon</surname><given-names>C. F.</given-names></name>; <name><surname>Roberts</surname><given-names>G. C.</given-names></name> (<year>2014</year>) <article-title>A variety
of roles for versatile
zinc in metallo-beta-lactamases,</article-title>. <source>Metallomics</source>
<volume>6</volume>, <fpage>1181</fpage>&#x02013;<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1039/C4MT00066H</pub-id>.<pub-id pub-id-type="pmid">24696003</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Fisher</surname><given-names>J. F.</given-names></name>; <name><surname>Meroueh</surname><given-names>S. O.</given-names></name>; <name><surname>Mobashery</surname><given-names>S.</given-names></name> (<year>2005</year>) <article-title>Bacterial
resistance to beta-lactam
antibiotics: compelling opportunism, compelling opportunity</article-title>. <source>Chem. Rev.</source>
<volume>105</volume>, <fpage>395</fpage>&#x02013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1021/cr030102i</pub-id>.<pub-id pub-id-type="pmid">15700950</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Bush</surname><given-names>K.</given-names></name> (<year>2010</year>) <article-title>Alarming beta-lactamase-mediated
resistance in multidrug-resistant Enterobacteriaceae</article-title>. <source>Curr. Opin. Microbiol.</source>
<volume>13</volume>, <fpage>558</fpage>&#x02013;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1016/j.mib.2010.09.006</pub-id>.<pub-id pub-id-type="pmid">20920882</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Palzkill</surname><given-names>T.</given-names></name> (<year>2013</year>) <article-title>Metallo-beta-lactamase
structure and function</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>1277</volume>, <fpage>91</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06796.x</pub-id>.<pub-id pub-id-type="pmid">23163348</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Galleni</surname><given-names>M.</given-names></name>; <name><surname>Lamotte-Brasseur</surname><given-names>J.</given-names></name>; <name><surname>Rossolini</surname><given-names>G. M.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Dideberg</surname><given-names>O.</given-names></name>; <name><surname>Fr&#x000e8;re</surname><given-names>J. M.</given-names></name> (<year>2001</year>) <article-title>Standard
numbering scheme for class B beta-lactamases</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>45</volume>, <fpage>660</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.45.3.660-663.2001</pub-id>.<pub-id pub-id-type="pmid">11181339</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Bebrone</surname><given-names>C.</given-names></name> (<year>2007</year>) <article-title>Metallo-beta-lactamases
(classification, activity, genetic organization, structure, zinc coordination)
and their superfamily</article-title>. <source>Biochem. Pharmacol.</source>
<volume>74</volume>, <fpage>1686</fpage>&#x02013;<lpage>1701</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2007.05.021</pub-id>.<pub-id pub-id-type="pmid">17597585</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Meini</surname><given-names>M. R.</given-names></name>; <name><surname>Llarrull</surname><given-names>L. I.</given-names></name>; <name><surname>Vila</surname><given-names>A. J.</given-names></name> (<year>2015</year>) <article-title>Overcoming
differences: The catalytic
mechanism of metallo-beta-lactamases,</article-title>. <source>FEBS
Lett.</source>
<volume>589</volume>, <fpage>3419</fpage>&#x02013;<lpage>3432</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2015.08.015</pub-id>.<pub-id pub-id-type="pmid">26297824</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Fonseca</surname><given-names>F.</given-names></name>; <name><surname>Bromley</surname><given-names>E. H.</given-names></name>; <name><surname>Saavedra</surname><given-names>M. J.</given-names></name>; <name><surname>Correia</surname><given-names>A.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name> (<year>2011</year>) <article-title>Crystal structure
of Serratia fonticola Sfh-I: activation of the nucleophile in mono-zinc
metallo-beta-lactamases</article-title>. <source>J. Mol. Biol.</source>
<volume>411</volume>, <fpage>951</fpage>&#x02013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2011.06.043</pub-id>.<pub-id pub-id-type="pmid">21762699</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Bush</surname><given-names>K.</given-names></name>; <name><surname>Jacoby</surname><given-names>G. A.</given-names></name> (<year>2010</year>) <article-title>Updated functional
classification of beta-lactamases</article-title>. <source>Antimicrob.
Agents Chemother.</source>
<volume>54</volume>, <fpage>969</fpage>&#x02013;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01009-09</pub-id>.<pub-id pub-id-type="pmid">19995920</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Fast</surname><given-names>W.</given-names></name>; <name><surname>Sutton</surname><given-names>L. D.</given-names></name> (<year>2013</year>) <article-title>Metallo-beta-lactamase: inhibitors and reporter substrates</article-title>. <source>Biochim. Biophys. Acta, Proteins Proteomics</source>
<volume>1834</volume>, <fpage>1648</fpage>&#x02013;<lpage>1659</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2013.04.024</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>van Berkel</surname><given-names>S. S.</given-names></name>; <name><surname>Zollman</surname><given-names>D.</given-names></name>; <name><surname>Lee</surname><given-names>S. Y.</given-names></name>; <name><surname>Gileadi</surname><given-names>O.</given-names></name>; <name><surname>McHugh</surname><given-names>P. J.</given-names></name>; <name><surname>Walsh</surname><given-names>T. R.</given-names></name>; <name><surname>McDonough</surname><given-names>M. A.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name> (<year>2016</year>) <article-title>Structural
Basis of Metallo-beta-Lactamase Inhibition
by Captopril Stereoisomers</article-title>. <source>Antimicrob. Agents
Chemother.</source>
<volume>60</volume>, <fpage>142</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01335-15</pub-id>.<pub-id pub-id-type="pmid">26482303</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Lienard</surname><given-names>B. M.</given-names></name>; <name><surname>Garau</surname><given-names>G.</given-names></name>; <name><surname>Horsfall</surname><given-names>L.</given-names></name>; <name><surname>Karsisiotis</surname><given-names>A. I.</given-names></name>; <name><surname>Damblon</surname><given-names>C.</given-names></name>; <name><surname>Lassaux</surname><given-names>P.</given-names></name>; <name><surname>Papamicael</surname><given-names>C.</given-names></name>; <name><surname>Roberts</surname><given-names>G. C.</given-names></name>; <name><surname>Galleni</surname><given-names>M.</given-names></name>; <name><surname>Dideberg</surname><given-names>O.</given-names></name>; <name><surname>Fr&#x000e8;re</surname><given-names>J. M.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name> (<year>2008</year>) <article-title>Structural basis for the broad-spectrum inhibition
of metallo-beta-lactamases by thiols</article-title>. <source>Org. Biomol.
Chem.</source>
<volume>6</volume>, <fpage>2282</fpage>&#x02013;<lpage>2294</lpage>. <pub-id pub-id-type="doi">10.1039/b802311e</pub-id>.<pub-id pub-id-type="pmid">18563261</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Gonz&#x000e1;lez</surname><given-names>M. M.</given-names></name>; <name><surname>Kosmopoulou</surname><given-names>M.</given-names></name>; <name><surname>Mojica</surname><given-names>M. F.</given-names></name>; <name><surname>Castillo</surname><given-names>V.</given-names></name>; <name><surname>Hinchliffe</surname><given-names>P.</given-names></name>; <name><surname>Pettinati</surname><given-names>I.</given-names></name>; <name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>; <name><surname>Mahler</surname><given-names>G.</given-names></name>; <name><surname>Bonomo</surname><given-names>R. A.</given-names></name>; <name><surname>Llarrull</surname><given-names>L. I.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Vila</surname><given-names>A. J.</given-names></name> (<year>2015</year>) <article-title>Bisthiazolidines: A Substrate-Mimicking Scaffold as
an Inhibitor of the NDM-1 Carbapenemase</article-title>. <source>ACS
Infect. Dis.</source>
<volume>1</volume>, <fpage>544</fpage>&#x02013;<lpage>554</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00046</pub-id>.<pub-id pub-id-type="pmid">27623409</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Mojica</surname><given-names>M. F.</given-names></name>; <name><surname>Mahler</surname><given-names>S. G.</given-names></name>; <name><surname>Bethel</surname><given-names>C. R.</given-names></name>; <name><surname>Taracila</surname><given-names>M. A.</given-names></name>; <name><surname>Kosmopoulou</surname><given-names>M.</given-names></name>; <name><surname>Papp-Wallace</surname><given-names>K. M.</given-names></name>; <name><surname>Llarrull</surname><given-names>L. I.</given-names></name>; <name><surname>Wilson</surname><given-names>B. M.</given-names></name>; <name><surname>Marshall</surname><given-names>S. H.</given-names></name>; <name><surname>Wallace</surname><given-names>C. J.</given-names></name>; <name><surname>Villegas</surname><given-names>M. V.</given-names></name>; <name><surname>Harris</surname><given-names>M. E.</given-names></name>; <name><surname>Vila</surname><given-names>A. J.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Bonomo</surname><given-names>R. A.</given-names></name> (<year>2015</year>) <article-title>Exploring the Role of Residue 228
in Substrate and Inhibitor Recognition by VIM Metallo-beta-lactamases</article-title>. <source>Biochemistry</source>
<volume>54</volume>, <fpage>3183</fpage>&#x02013;<lpage>3196</lpage>. <pub-id pub-id-type="doi">10.1021/acs.biochem.5b00106</pub-id>.<pub-id pub-id-type="pmid">25915520</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Hinchliffe</surname><given-names>P.</given-names></name>; <name><surname>Gonzalez</surname><given-names>M. M.</given-names></name>; <name><surname>Mojica</surname><given-names>M. F.</given-names></name>; <name><surname>Gonzalez</surname><given-names>J. M.</given-names></name>; <name><surname>Castillo</surname><given-names>V.</given-names></name>; <name><surname>Saiz</surname><given-names>C.</given-names></name>; <name><surname>Kosmopoulou</surname><given-names>M.</given-names></name>; <name><surname>Tooke</surname><given-names>C. L.</given-names></name>; <name><surname>Llarrull</surname><given-names>L. I.</given-names></name>; <name><surname>Mahler</surname><given-names>G.</given-names></name>; <name><surname>Bonomo</surname><given-names>R. A.</given-names></name>; <name><surname>Vila</surname><given-names>A. J.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name> (<year>2016</year>) <article-title>Cross-class
metallo-beta-lactamase inhibition by bisthiazolidines reveals multiple
binding modes</article-title>. <source>Proc. Natl. Acad. Sci. U. S.
A.</source>
<volume>113</volume>, <fpage>E3745</fpage>&#x02013;<lpage>3754</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1601368113</pub-id>.<pub-id pub-id-type="pmid">27303030</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Read</surname><given-names>J.</given-names></name>; <name><surname>Sessions</surname><given-names>R. B.</given-names></name>; <name><surname>Howell</surname><given-names>S.</given-names></name>; <name><surname>Blackburn</surname><given-names>G. M.</given-names></name>; <name><surname>Gamblin</surname><given-names>S. J.</given-names></name> (<year>2005</year>) <article-title>Antibiotic Recognition by Binuclear Metallo-&#x003b2;-Lactamases
Revealed by X-ray Crystallography</article-title>. <source>J. Am. Chem.
Soc.</source>
<volume>127</volume>, <fpage>14439</fpage>&#x02013;<lpage>14444</lpage>. <pub-id pub-id-type="doi">10.1021/ja0536062</pub-id>.<pub-id pub-id-type="pmid">16218639</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Feng</surname><given-names>H.</given-names></name>; <name><surname>Ding</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>D.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Zang</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>D. C.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name> (<year>2014</year>) <article-title>Structural
and mechanistic insights into NDM-1 catalyzed hydrolysis of cephalosporins</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>136</volume>, <fpage>14694</fpage>&#x02013;<lpage>14697</lpage>. <pub-id pub-id-type="doi">10.1021/ja508388e</pub-id>.<pub-id pub-id-type="pmid">25268575</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>van Berkel</surname><given-names>S. S.</given-names></name>; <name><surname>Aik</surname><given-names>W.</given-names></name>; <name><surname>Rydzik</surname><given-names>A. M.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name>; <name><surname>Pettinati</surname><given-names>I.</given-names></name>; <name><surname>Umland</surname><given-names>K. D.</given-names></name>; <name><surname>Kawamura</surname><given-names>A.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Claridge</surname><given-names>T. D.</given-names></name>; <name><surname>McDonough</surname><given-names>M. A.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name> (<year>2014</year>) <article-title>Rhodanine
hydrolysis leads to potent thioenolate mediated metallo-beta-lactamase
inhibition</article-title>. <source>Nat. Chem.</source>
<volume>6</volume>, <fpage>1084</fpage>&#x02013;<lpage>1090</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.2110</pub-id>.<pub-id pub-id-type="pmid">25411887</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Garc&#x000ed;a-S&#x000e1;ez</surname><given-names>I.</given-names></name>; <name><surname>Hopkins</surname><given-names>J.</given-names></name>; <name><surname>Papamicael</surname><given-names>C.</given-names></name>; <name><surname>Franceschini</surname><given-names>N.</given-names></name>; <name><surname>Amicosante</surname><given-names>G.</given-names></name>; <name><surname>Rossolini</surname><given-names>G. M.</given-names></name>; <name><surname>Galleni</surname><given-names>M.</given-names></name>; <name><surname>Fr&#x000e8;re</surname><given-names>J. M.</given-names></name>; <name><surname>Dideberg</surname><given-names>O.</given-names></name> (<year>2003</year>) <article-title>The 1.5-A structure of Chryseobacterium meningosepticum
zinc beta-lactamase in complex with the inhibitor, D-captopril,</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>23868</fpage>&#x02013;<lpage>23873</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M301062200</pub-id>.<pub-id pub-id-type="pmid">12684522</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Kurosaki</surname><given-names>H.</given-names></name>; <name><surname>Yamaguchi</surname><given-names>Y.</given-names></name>; <name><surname>Yasuzawa</surname><given-names>H.</given-names></name>; <name><surname>Jin</surname><given-names>W.</given-names></name>; <name><surname>Yamagata</surname><given-names>Y.</given-names></name>; <name><surname>Arakawa</surname><given-names>Y.</given-names></name> (<year>2006</year>) <article-title>Probing, inhibition, and crystallographic characterization
of metallo-beta-lactamase (IMP-1) with fluorescent agents containing
dansyl and thiol groups</article-title>. <source>ChemMedChem</source>
<volume>1</volume>, <fpage>969</fpage>&#x02013;<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.200600115</pub-id>.<pub-id pub-id-type="pmid">16937423</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Yamaguchi</surname><given-names>Y.</given-names></name>; <name><surname>Jin</surname><given-names>W.</given-names></name>; <name><surname>Matsunaga</surname><given-names>K.</given-names></name>; <name><surname>Ikemizu</surname><given-names>S.</given-names></name>; <name><surname>Yamagata</surname><given-names>Y.</given-names></name>; <name><surname>Wachino</surname><given-names>J.</given-names></name>; <name><surname>Shibata</surname><given-names>N.</given-names></name>; <name><surname>Arakawa</surname><given-names>Y.</given-names></name>; <name><surname>Kurosaki</surname><given-names>H.</given-names></name> (<year>2007</year>) <article-title>Crystallographic investigation
of the inhibition mode of a VIM-2 metallo-beta-lactamase from Pseudomonas
aeruginosa by a mercaptocarboxylate inhibitor</article-title>. <source>J. Med. Chem.</source>
<volume>50</volume>, <fpage>6647</fpage>&#x02013;<lpage>6653</lpage>. <pub-id pub-id-type="doi">10.1021/jm701031n</pub-id>.<pub-id pub-id-type="pmid">18052313</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Wachino</surname><given-names>J.</given-names></name>; <name><surname>Yamaguchi</surname><given-names>Y.</given-names></name>; <name><surname>Mori</surname><given-names>S.</given-names></name>; <name><surname>Kurosaki</surname><given-names>H.</given-names></name>; <name><surname>Arakawa</surname><given-names>Y.</given-names></name>; <name><surname>Shibayama</surname><given-names>K.</given-names></name> (<year>2013</year>) <article-title>Structural insights into the subclass B3 metallo-beta-lactamase
SMB-1 and the mode of inhibition by the common metallo-beta-lactamase
inhibitor mercaptoacetate</article-title>. <source>Antimicrob. Agents
Chemother.</source>
<volume>57</volume>, <fpage>101</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01264-12</pub-id>.<pub-id pub-id-type="pmid">23070156</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Nauton</surname><given-names>L.</given-names></name>; <name><surname>Kahn</surname><given-names>R.</given-names></name>; <name><surname>Garau</surname><given-names>G.</given-names></name>; <name><surname>Hernandez</surname><given-names>J. F.</given-names></name>; <name><surname>Dideberg</surname><given-names>O.</given-names></name> (<year>2008</year>) <article-title>Structural insights into the design of inhibitors for
the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia</article-title>. <source>J. Mol. Biol.</source>
<volume>375</volume>, <fpage>257</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2007.10.036</pub-id>.<pub-id pub-id-type="pmid">17999929</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Lassaux</surname><given-names>P.</given-names></name>; <name><surname>Hamel</surname><given-names>M.</given-names></name>; <name><surname>Gulea</surname><given-names>M.</given-names></name>; <name><surname>Delbruck</surname><given-names>H.</given-names></name>; <name><surname>Mercuri</surname><given-names>P. S.</given-names></name>; <name><surname>Horsfall</surname><given-names>L.</given-names></name>; <name><surname>Dehareng</surname><given-names>D.</given-names></name>; <name><surname>Kupper</surname><given-names>M.</given-names></name>; <name><surname>Fr&#x000e8;re</surname><given-names>J. M.</given-names></name>; <name><surname>Hoffmann</surname><given-names>K.</given-names></name>; <name><surname>Galleni</surname><given-names>M.</given-names></name>; <name><surname>Bebrone</surname><given-names>C.</given-names></name> (<year>2010</year>) <article-title>Mercaptophosphonate
compounds as broad-spectrum inhibitors of the metallo-beta-lactamases</article-title>. <source>J. Med. Chem.</source>
<volume>53</volume>, <fpage>4862</fpage>&#x02013;<lpage>4876</lpage>. <pub-id pub-id-type="doi">10.1021/jm100213c</pub-id>.<pub-id pub-id-type="pmid">20527888</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Toney</surname><given-names>J. H.</given-names></name>; <name><surname>Cleary</surname><given-names>K. A.</given-names></name>; <name><surname>Hammond</surname><given-names>G. G.</given-names></name>; <name><surname>Yuan</surname><given-names>X.</given-names></name>; <name><surname>May</surname><given-names>W. J.</given-names></name>; <name><surname>Hutchins</surname><given-names>S. M.</given-names></name>; <name><surname>Ashton</surname><given-names>W. T.</given-names></name>; <name><surname>Vanderwall</surname><given-names>D. E.</given-names></name> (<year>1999</year>) <article-title>Structure-activity
relationships of biphenyl tetrazoles as metallo-beta-lactamase inhibitors</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<volume>9</volume>, <fpage>2741</fpage>&#x02013;<lpage>2746</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-894X(99)00458-8</pub-id>.<pub-id pub-id-type="pmid">10509927</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Hiraiwa</surname><given-names>Y.</given-names></name>; <name><surname>Saito</surname><given-names>J.</given-names></name>; <name><surname>Watanabe</surname><given-names>T.</given-names></name>; <name><surname>Yamada</surname><given-names>M.</given-names></name>; <name><surname>Morinaka</surname><given-names>A.</given-names></name>; <name><surname>Fukushima</surname><given-names>T.</given-names></name>; <name><surname>Kudo</surname><given-names>T.</given-names></name> (<year>2014</year>) <article-title>X-ray crystallographic analysis of
IMP-1 metallo-beta-lactamase complexed with a 3-aminophthalic acid
derivative, structure-based drug design, and synthesis of 3,6-disubstituted
phthalic acid derivative inhibitors</article-title>. <source>Bioorg.
Med. Chem. Lett.</source>
<volume>24</volume>, <fpage>4891</fpage>&#x02013;<lpage>4894</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2014.08.039</pub-id>.<pub-id pub-id-type="pmid">25246278</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Horsfall</surname><given-names>L. E.</given-names></name>; <name><surname>Garau</surname><given-names>G.</given-names></name>; <name><surname>Lienard</surname><given-names>B. M.</given-names></name>; <name><surname>Dideberg</surname><given-names>O.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>; <name><surname>Fr&#x000e8;re</surname><given-names>J. M.</given-names></name>; <name><surname>Galleni</surname><given-names>M.</given-names></name> (<year>2007</year>) <article-title>Competitive inhibitors
of the CphA
metallo-beta-lactamase from Aeromonas hydrophila</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>51</volume>, <fpage>2136</fpage>&#x02013;<lpage>2142</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00866-06</pub-id>.<pub-id pub-id-type="pmid">17307979</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Toney</surname><given-names>J. H.</given-names></name>; <name><surname>Fitzgerald</surname><given-names>P. M.</given-names></name>; <name><surname>Grover-Sharma</surname><given-names>N.</given-names></name>; <name><surname>Olson</surname><given-names>S. H.</given-names></name>; <name><surname>May</surname><given-names>W. J.</given-names></name>; <name><surname>Sundelof</surname><given-names>J. G.</given-names></name>; <name><surname>Vanderwall</surname><given-names>D. E.</given-names></name>; <name><surname>Cleary</surname><given-names>K. A.</given-names></name>; <name><surname>Grant</surname><given-names>S. K.</given-names></name>; <name><surname>Wu</surname><given-names>J. K.</given-names></name>; <name><surname>Kozarich</surname><given-names>J. W.</given-names></name>; <name><surname>Pompliano</surname><given-names>D. L.</given-names></name>; <name><surname>Hammond</surname><given-names>G. G.</given-names></name> (<year>1998</year>) <article-title>Antibiotic sensitization using biphenyl tetrazoles
as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase</article-title>. <source>Chem. Biol.</source>
<volume>5</volume>, <fpage>185</fpage>&#x02013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-5521(98)90632-9</pub-id>.<pub-id pub-id-type="pmid">9545432</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Docquier</surname><given-names>J. D.</given-names></name>; <name><surname>Benvenuti</surname><given-names>M.</given-names></name>; <name><surname>Calderone</surname><given-names>V.</given-names></name>; <name><surname>Stoczko</surname><given-names>M.</given-names></name>; <name><surname>Menciassi</surname><given-names>N.</given-names></name>; <name><surname>Rossolini</surname><given-names>G. M.</given-names></name>; <name><surname>Mangani</surname><given-names>S.</given-names></name> (<year>2010</year>) <article-title>High-resolution crystal structure
of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for
substrate specificity and interaction with sulfonamides</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>54</volume>, <fpage>4343</fpage>&#x02013;<lpage>4351</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00409-10</pub-id>.<pub-id pub-id-type="pmid">20696874</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Cain</surname><given-names>R.</given-names></name>; <name><surname>Cahill</surname><given-names>S.</given-names></name>; <name><surname>McDonough</surname><given-names>M. A.</given-names></name>; <name><surname>Clifton</surname><given-names>I. J.</given-names></name>; <name><surname>Jimenez-Castellanos</surname><given-names>J.
C.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Fishwick</surname><given-names>C. W.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name> (<year>2016</year>) <article-title>Structural
basis of metallo-beta-lactamase, serine-beta-lactamase and penicillin-binding
protein inhibition by cyclic boronates</article-title>. <source>Nat.
Commun.</source>
<volume>7</volume>, <fpage>12406</fpage><pub-id pub-id-type="doi">10.1038/ncomms12406</pub-id>.<pub-id pub-id-type="pmid">27499424</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Calvopina</surname><given-names>K.</given-names></name>; <name><surname>Hinchliffe</surname><given-names>P.</given-names></name>; <name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Heesom</surname><given-names>K. J.</given-names></name>; <name><surname>Johnson</surname><given-names>S.</given-names></name>; <name><surname>Cain</surname><given-names>R.</given-names></name>; <name><surname>Lohans</surname><given-names>C. T.</given-names></name>; <name><surname>Fishwick</surname><given-names>C. W. G.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name> (<year>2017</year>) <article-title>Structural/mechanistic insights into
the efficacy of nonclassical beta-lactamase inhibitors against extensively
drug resistant Stenotrophomonas maltophilia clinical isolates</article-title>. <source>Mol. Microbiol.</source>
<volume>106</volume>, <fpage>492</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.13831</pub-id>.<pub-id pub-id-type="pmid">28876489</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Jacobsen</surname><given-names>J. A.</given-names></name>; <name><surname>Major Jourden</surname><given-names>J. L.</given-names></name>; <name><surname>Miller</surname><given-names>M. T.</given-names></name>; <name><surname>Cohen</surname><given-names>S. M.</given-names></name> (<year>2010</year>) <article-title>To bind zinc or
not to bind zinc: an examination of innovative approaches to improved
metalloproteinase inhibition</article-title>. <source>Biochim. Biophys.
Acta, Mol. Cell Res.</source>
<volume>1803</volume>, <fpage>72</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2009.08.006</pub-id>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Temperini</surname><given-names>C.</given-names></name>; <name><surname>Innocenti</surname><given-names>A.</given-names></name>; <name><surname>Guerri</surname><given-names>A.</given-names></name>; <name><surname>Scozzafava</surname><given-names>A.</given-names></name>; <name><surname>Rusconi</surname><given-names>S.</given-names></name>; <name><surname>Supuran</surname><given-names>C. T.</given-names></name> (<year>2007</year>) <article-title>Phosph(on)ate as a zinc-binding group
in metalloenzyme inhibitors: X-ray crystal structure of the antiviral
drug foscarnet complexed to human carbonic anhydrase I</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<volume>17</volume>, <fpage>2210</fpage>&#x02013;<lpage>2215</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.01.113</pub-id>.<pub-id pub-id-type="pmid">17314045</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Tronrud</surname><given-names>D. E.</given-names></name>; <name><surname>Monzingo</surname><given-names>A. F.</given-names></name>; <name><surname>Matthews</surname><given-names>B. W.</given-names></name> (<year>1986</year>) <article-title>Crystallographic
structural analysis
of phosphoramidates as inhibitors and transition-state analogs of
thermolysin</article-title>. <source>Eur. J. Biochem.</source>
<volume>157</volume>, <fpage>261</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1986.tb09664.x</pub-id>.<pub-id pub-id-type="pmid">3709536</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Maveyraud</surname><given-names>L.</given-names></name>; <name><surname>Pratt</surname><given-names>R. F.</given-names></name>; <name><surname>Samama</surname><given-names>J. P.</given-names></name> (<year>1998</year>) <article-title>Crystal
structure of an acylation
transition-state analog of the TEM-1 beta-lactamase. Mechanistic implications
for class A beta-lactamases</article-title>. <source>Biochemistry</source>
<volume>37</volume>, <fpage>2622</fpage>&#x02013;<lpage>2628</lpage>. <pub-id pub-id-type="doi">10.1021/bi972501b</pub-id>.<pub-id pub-id-type="pmid">9485412</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Chen</surname><given-names>C. C.</given-names></name>; <name><surname>Rahil</surname><given-names>J.</given-names></name>; <name><surname>Pratt</surname><given-names>R. F.</given-names></name>; <name><surname>Herzberg</surname><given-names>O.</given-names></name> (<year>1993</year>) <article-title>Structure of a phosphonate-inhibited
beta-lactamase. An analog of the tetrahedral transition state/intermediate
of beta-lactam hydrolysis</article-title>. <source>J. Mol. Biol.</source>
<volume>234</volume>, <fpage>165</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1993.1571</pub-id>.<pub-id pub-id-type="pmid">8230196</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Yang</surname><given-names>K. W.</given-names></name>; <name><surname>Feng</surname><given-names>L.</given-names></name>; <name><surname>Yang</surname><given-names>S. K.</given-names></name>; <name><surname>Aitha</surname><given-names>M.</given-names></name>; <name><surname>LaCuran</surname><given-names>A. E.</given-names></name>; <name><surname>Oelschlaeger</surname><given-names>P.</given-names></name>; <name><surname>Crowder</surname><given-names>M. W.</given-names></name> (<year>2013</year>) <article-title>New beta-phospholactam as a carbapenem
transition state analog: Synthesis of a broad-spectrum inhibitor of
metallo-beta-lactamases</article-title>. <source>Bioorg. Med. Chem.
Lett.</source>
<volume>23</volume>, <fpage>5855</fpage>&#x02013;<lpage>5859</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2013.08.098</pub-id>.<pub-id pub-id-type="pmid">24064498</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Lee</surname><given-names>M.</given-names></name>; <name><surname>Hesek</surname><given-names>D.</given-names></name>; <name><surname>Mobashery</surname><given-names>S.</given-names></name> (<year>2005</year>) <article-title>A practical synthesis of nitrocefin,</article-title>. <source>J. Org. Chem.</source>
<volume>70</volume>, <fpage>367</fpage>&#x02013;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1021/jo0487395</pub-id>.<pub-id pub-id-type="pmid">15624952</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Labb&#x000e9;</surname><given-names>G.</given-names></name>; <name><surname>Krismanich</surname><given-names>A. P.</given-names></name>; <name><surname>de Groot</surname><given-names>S.</given-names></name>; <name><surname>Rasmusson</surname><given-names>T.</given-names></name>; <name><surname>Shang</surname><given-names>M.</given-names></name>; <name><surname>Brown</surname><given-names>M. D.</given-names></name>; <name><surname>Dmitrienko</surname><given-names>G. I.</given-names></name>; <name><surname>Guillemette</surname><given-names>J. G.</given-names></name> (<year>2012</year>) <article-title>Development of metal-chelating inhibitors for the Class
II fructose 1,6-bisphosphate (FBP) aldolase</article-title>. <source>J. Inorg. Biochem.</source>
<volume>112</volume>, <fpage>49</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2012.02.032</pub-id>.<pub-id pub-id-type="pmid">22546686</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Li</surname><given-names>G. B.</given-names></name>; <name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Lesniak</surname><given-names>R.</given-names></name>; <name><surname>Abboud</surname><given-names>M. I.</given-names></name>; <name><surname>Lohans</surname><given-names>C. T.</given-names></name>; <name><surname>Clifton</surname><given-names>I. J.</given-names></name>; <name><surname>Yang</surname><given-names>S. Y.</given-names></name>; <name><surname>Jimenez-Castellanos</surname><given-names>J. C.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>McDonough</surname><given-names>M. A.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name> (<year>2017</year>) <article-title>Crystallographic analyses of isoquinoline
complexes
reveal a new mode of metallo-beta-lactamase inhibition</article-title>. <source>Chem. Commun. (Cambridge, U. K.)</source>
<volume>53</volume>, <fpage>5806</fpage>&#x02013;<lpage>5809</lpage>. <pub-id pub-id-type="doi">10.1039/C7CC02394D</pub-id>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>King</surname><given-names>A. M.</given-names></name>; <name><surname>Reid-Yu</surname><given-names>S. A.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>King</surname><given-names>D. T.</given-names></name>; <name><surname>De Pascale</surname><given-names>G.</given-names></name>; <name><surname>Strynadka</surname><given-names>N. C.</given-names></name>; <name><surname>Walsh</surname><given-names>T. R.</given-names></name>; <name><surname>Coombes</surname><given-names>B. K.</given-names></name>; <name><surname>Wright</surname><given-names>G. D.</given-names></name> (<year>2014</year>) <article-title>Aspergillomarasmine
A overcomes metallo-beta-lactamase antibiotic resistance</article-title>. <source>Nature</source>
<volume>510</volume>, <fpage>503</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1038/nature13445</pub-id>.<pub-id pub-id-type="pmid">24965651</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Crossman</surname><given-names>L. C.</given-names></name>; <name><surname>Gould</surname><given-names>V. C.</given-names></name>; <name><surname>Dow</surname><given-names>J. M.</given-names></name>; <name><surname>Vernikos</surname><given-names>G. S.</given-names></name>; <name><surname>Okazaki</surname><given-names>A.</given-names></name>; <name><surname>Sebaihia</surname><given-names>M.</given-names></name>; <name><surname>Saunders</surname><given-names>D.</given-names></name>; <name><surname>Arrowsmith</surname><given-names>C.</given-names></name>; <name><surname>Carver</surname><given-names>T.</given-names></name>; <name><surname>Peters</surname><given-names>N.</given-names></name>; <name><surname>Adlem</surname><given-names>E.</given-names></name>; <name><surname>Kerhornou</surname><given-names>A.</given-names></name>; <name><surname>Lord</surname><given-names>A.</given-names></name>; <name><surname>Murphy</surname><given-names>L.</given-names></name>; <name><surname>Seeger</surname><given-names>K.</given-names></name>; <name><surname>Squares</surname><given-names>R.</given-names></name>; <name><surname>Rutter</surname><given-names>S.</given-names></name>; <name><surname>Quail</surname><given-names>M. A.</given-names></name>; <name><surname>Rajandream</surname><given-names>M.-A.</given-names></name>; <name><surname>Harris</surname><given-names>D.</given-names></name>; <name><surname>Churcher</surname><given-names>C.</given-names></name>; <name><surname>Bentley</surname><given-names>S. D.</given-names></name>; <name><surname>Parkhill</surname><given-names>J.</given-names></name>; <name><surname>Thomson</surname><given-names>N. R.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name> (<year>2008</year>) <article-title>The complete genome, comparative
and functional analysis of Stenotrophomonas maltophiliareveals an
organism heavily shielded by drug resistance determinants,</article-title>. <source>Genome Biol.</source>
<volume>9</volume>, <fpage>R74</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-4-r74</pub-id>.<pub-id pub-id-type="pmid">18419807</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Gould</surname><given-names>V. C.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name> (<year>2006</year>) <article-title>SmeDEF-mediated
antimicrobial drug resistance in Stenotrophomonas
maltophilia clinical isolates having defined phylogenetic relationships</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>57</volume>, <fpage>1070</fpage>&#x02013;<lpage>1076</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkl106</pub-id>.<pub-id pub-id-type="pmid">16597633</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Gould</surname><given-names>V. C.</given-names></name>; <name><surname>Okazaki</surname><given-names>A.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name> (<year>2013</year>) <article-title>Coordinate
hyperproduction of SmeZ
and SmeJK efflux pumps extends drug resistance in Stenotrophomonas
maltophilia</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>57</volume>, <fpage>655</fpage>&#x02013;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01020-12</pub-id>.<pub-id pub-id-type="pmid">23147729</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="book" id="cit48"><person-group person-group-type="allauthors"><collab>CLSI</collab></person-group> (<year>2014</year>) <article-title>Performance Standards
for Antimicrobial
Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24</article-title>. Technical Report, <publisher-name>CLSI</publisher-name>, <publisher-loc>Wayne, PA</publisher-loc>.</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="book" id="cit49"><person-group person-group-type="allauthors"><name><surname>Dayeh</surname><given-names>V. R.</given-names></name>, <name><surname>Schirmer</surname><given-names>K.</given-names></name>, <name><surname>Lee</surname><given-names>L.
E. J.</given-names></name>, and <name><surname>Bols</surname><given-names>N. C.</given-names></name></person-group> (<year>2003</year>) <article-title>The use of fish-derived cell lines for investigation of environmental
contaminants</article-title>. In <source>Current Protocols in Toxicology</source>, Unit 1.5, pp <fpage>1</fpage>&#x02013;<lpage>17</lpage>, <publisher-name>Wiley</publisher-name>, <publisher-loc>New York</publisher-loc>.</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="book" id="cit50"><person-group person-group-type="allauthors"><name><surname>Ganassin</surname><given-names>R. C.</given-names></name>, <name><surname>Schirmer</surname><given-names>K.</given-names></name>, and <name><surname>Bols</surname><given-names>N. C.</given-names></name></person-group> (<year>2000</year>) <article-title>Methods for the use of fish cell and tissue cultures as model systems
in basic and toxicology research</article-title>. In <source>The Laboratory
Fish</source> (<person-group person-group-type="editor"><name><surname>Ostrander</surname><given-names>G. K.</given-names></name></person-group>, Ed.) pp <fpage>631</fpage>&#x02013;<lpage>651</lpage>, <publisher-name>Academic Press</publisher-name>, <publisher-loc>San Diego</publisher-loc>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Ullah</surname><given-names>J. H.</given-names></name>; <name><surname>Walsh</surname><given-names>T. R.</given-names></name>; <name><surname>Taylor</surname><given-names>I. A.</given-names></name>; <name><surname>Emery</surname><given-names>D. C.</given-names></name>; <name><surname>Verma</surname><given-names>C. S.</given-names></name>; <name><surname>Gamblin</surname><given-names>S. J.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name> (<year>1998</year>) <article-title>The crystal
structure of the L1 metallo-beta-lactamase
from Stenotrophomonas maltophilia at 1.7 A resolution,</article-title>. <source>J. Mol. Biol.</source>
<volume>284</volume>, <fpage>125</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1998.2148</pub-id>.<pub-id pub-id-type="pmid">9811546</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>van
Berkel</surname><given-names>S. S.</given-names></name>; <name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Rydzik</surname><given-names>A. M.</given-names></name>; <name><surname>Salimraj</surname><given-names>R.</given-names></name>; <name><surname>Cain</surname><given-names>R.</given-names></name>; <name><surname>Verma</surname><given-names>A.</given-names></name>; <name><surname>Owens</surname><given-names>R. J.</given-names></name>; <name><surname>Fishwick</surname><given-names>C. W.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name> (<year>2013</year>) <article-title>Assay platform for clinically relevant
metallo-beta-lactamases</article-title>. <source>J. Med. Chem.</source>
<volume>56</volume>, <fpage>6945</fpage>&#x02013;<lpage>6953</lpage>. <pub-id pub-id-type="doi">10.1021/jm400769b</pub-id>.<pub-id pub-id-type="pmid">23898798</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Ghavami</surname><given-names>A.</given-names></name>; <name><surname>Labb&#x000e9;</surname><given-names>G.</given-names></name>; <name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Goodfellow</surname><given-names>V. J.</given-names></name>; <name><surname>Marrone</surname><given-names>L.</given-names></name>; <name><surname>Tanner</surname><given-names>C. A.</given-names></name>; <name><surname>King</surname><given-names>D. T.</given-names></name>; <name><surname>Lam</surname><given-names>M.</given-names></name>; <name><surname>Strynadka</surname><given-names>N. C.</given-names></name>; <name><surname>Pillai</surname><given-names>D. R.</given-names></name>; <name><surname>Siemann</surname><given-names>S.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>; <name><surname>Dmitrienko</surname><given-names>G. I.</given-names></name> (<year>2015</year>) <article-title>Assay for drug discovery: Synthesis
and testing of nitrocefin analogues for use as beta-lactamase substrates</article-title>. <source>Anal. Biochem.</source>
<volume>486</volume>, <fpage>75</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2015.06.032</pub-id>.<pub-id pub-id-type="pmid">26142222</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Morrison</surname><given-names>J. F.</given-names></name>; <name><surname>Walsh</surname><given-names>C. T.</given-names></name> (<year>2006</year>) <article-title>The behavior and significance of
slow-binding enzyme
inhibitors,</article-title>. <source>Adv. Enzymol. Relat. Areas Mol.
Biol.</source>
<volume>61</volume>, <fpage>201</fpage>&#x02013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1002/9780470123072.ch5</pub-id>.</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Goli&#x0010d;nik</surname><given-names>M.</given-names></name>; <name><surname>Stojan</surname><given-names>J.</given-names></name> (<year>2004</year>) <article-title>Slow-binding inhibition: A theoretical and practical
course for students,</article-title>. <source>Biochem. Mol. Biol. Educ.</source>
<volume>32</volume>, <fpage>228</fpage>&#x02013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1002/bmb.2004.494032040358</pub-id>.<pub-id pub-id-type="pmid">21706729</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Kabsch</surname><given-names>W.</given-names></name> (<year>2010</year>) <article-title>Xds</article-title>. <source>Acta Crystallogr.,
Sect. D: Biol. Crystallogr.</source>
<volume>66</volume>, <fpage>125</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id>.<pub-id pub-id-type="pmid">20124692</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Evans</surname><given-names>P. R.</given-names></name> (<year>2011</year>) <article-title>An introduction
to data reduction: space-group determination, scaling and intensity
statistics</article-title>. <source>Acta Crystallogr., Sect. D: Biol.
Crystallogr.</source>
<volume>67</volume>, <fpage>282</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1107/S090744491003982X</pub-id>.<pub-id pub-id-type="pmid">21460446</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>McCoy</surname><given-names>A. J.</given-names></name>; <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>; <name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Winn</surname><given-names>M. D.</given-names></name>; <name><surname>Storoni</surname><given-names>L. C.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name> (<year>2007</year>) <article-title>Phaser crystallographic software</article-title>. <source>J. Appl. Crystallogr.</source>
<volume>40</volume>, <fpage>658</fpage>&#x02013;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id>.<pub-id pub-id-type="pmid">19461840</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Emsley</surname><given-names>P.</given-names></name>; <name><surname>Lohkamp</surname><given-names>B.</given-names></name>; <name><surname>Scott</surname><given-names>W. G.</given-names></name>; <name><surname>Cowtan</surname><given-names>K.</given-names></name> (<year>2010</year>) <article-title>Features and
development
of Coot</article-title>. <source>Acta Crystallogr., Sect. D: Biol. Crystallogr.</source>
<volume>66</volume>, <fpage>486</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id>.<pub-id pub-id-type="pmid">20383002</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Adams</surname><given-names>P. D.</given-names></name>; <name><surname>Afonine</surname><given-names>P. V.</given-names></name>; <name><surname>Bunkoczi</surname><given-names>G.</given-names></name>; <name><surname>Chen</surname><given-names>V. B.</given-names></name>; <name><surname>Davis</surname><given-names>I. W.</given-names></name>; <name><surname>Echols</surname><given-names>N.</given-names></name>; <name><surname>Headd</surname><given-names>J. J.</given-names></name>; <name><surname>Hung</surname><given-names>L. W.</given-names></name>; <name><surname>Kapral</surname><given-names>G. J.</given-names></name>; <name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name>; <name><surname>McCoy</surname><given-names>A. J.</given-names></name>; <name><surname>Moriarty</surname><given-names>N. W.</given-names></name>; <name><surname>Oeffner</surname><given-names>R.</given-names></name>; <name><surname>Read</surname><given-names>R. J.</given-names></name>; <name><surname>Richardson</surname><given-names>D. C.</given-names></name>; <name><surname>Richardson</surname><given-names>J. S.</given-names></name>; <name><surname>Terwilliger</surname><given-names>T. C.</given-names></name>; <name><surname>Zwart</surname><given-names>P. H.</given-names></name> (<year>2010</year>) <article-title>PHENIX: a comprehensive Python-based
system for macromolecular structure solution</article-title>. <source>Acta Crystallogr., Sect. D: Biol. Crystallogr.</source>
<volume>66</volume>, <fpage>213</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id>.<pub-id pub-id-type="pmid">20124702</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Chen</surname><given-names>V. B.</given-names></name>; <name><surname>Arendall</surname><given-names>W. B.</given-names><suffix>3rd</suffix></name>; <name><surname>Headd</surname><given-names>J. J.</given-names></name>; <name><surname>Keedy</surname><given-names>D. A.</given-names></name>; <name><surname>Immormino</surname><given-names>R. M.</given-names></name>; <name><surname>Kapral</surname><given-names>G. J.</given-names></name>; <name><surname>Murray</surname><given-names>L. W.</given-names></name>; <name><surname>Richardson</surname><given-names>J. S.</given-names></name>; <name><surname>Richardson</surname><given-names>D. C.</given-names></name> (<year>2010</year>) <article-title>MolProbity: all-atom structure validation for macromolecular
crystallography</article-title>. <source>Acta Crystallogr., Sect. D:
Biol. Crystallogr.</source>
<volume>66</volume>, <fpage>12</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id>.<pub-id pub-id-type="pmid">20057044</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Roll</surname><given-names>D. M.</given-names></name>; <name><surname>Yang</surname><given-names>Y.</given-names></name>; <name><surname>Wildey</surname><given-names>M. J.</given-names></name>; <name><surname>Bush</surname><given-names>K.</given-names></name>; <name><surname>Lee</surname><given-names>M. D.</given-names></name> (<year>2010</year>) <article-title>Inhibition
of metallo-beta-lactamases by pyridine monothiocarboxylic acid analogs</article-title>. <source>J. Antibiot.</source>
<volume>63</volume>, <fpage>255</fpage>&#x02013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1038/ja.2010.20</pub-id>.<pub-id pub-id-type="pmid">20224603</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Siemann</surname><given-names>S.</given-names></name>; <name><surname>Brewer</surname><given-names>D.</given-names></name>; <name><surname>Clarke</surname><given-names>A. J.</given-names></name>; <name><surname>Dmitrienko</surname><given-names>G. I.</given-names></name>; <name><surname>Lajoie</surname><given-names>G.</given-names></name>; <name><surname>Viswanatha</surname><given-names>T.</given-names></name> (<year>2002</year>) <article-title>IMP-1 metallo-beta-lactamase: effect
of chelators and assessment of metal requirement by electrospray mass
spectrometry</article-title>. <source>Biochim. Biophys. Acta, Gen. Subj.</source>
<volume>1571</volume>, <fpage>190</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-4165(02)00258-1</pub-id>.</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Chen</surname><given-names>A. Y.</given-names></name>; <name><surname>Thomas</surname><given-names>P. W.</given-names></name>; <name><surname>Stewart</surname><given-names>A. C.</given-names></name>; <name><surname>Bergstrom</surname><given-names>A.</given-names></name>; <name><surname>Cheng</surname><given-names>Z.</given-names></name>; <name><surname>Miller</surname><given-names>C.</given-names></name>; <name><surname>Bethel</surname><given-names>C. R.</given-names></name>; <name><surname>Marshall</surname><given-names>S. H.</given-names></name>; <name><surname>Credille</surname><given-names>C. V.</given-names></name>; <name><surname>Riley</surname><given-names>C. L.</given-names></name>; <name><surname>Page</surname><given-names>R. C.</given-names></name>; <name><surname>Bonomo</surname><given-names>R. A.</given-names></name>; <name><surname>Crowder</surname><given-names>M. W.</given-names></name>; <name><surname>Tierney</surname><given-names>D. L.</given-names></name>; <name><surname>Fast</surname><given-names>W.</given-names></name>; <name><surname>Cohen</surname><given-names>S. M.</given-names></name> (<year>2017</year>) <article-title>Dipicolinic
Acid Derivatives as Inhibitors of New Delhi Metallo-beta-lactamase-1</article-title>. <source>J. Med. Chem.</source>
<volume>60</volume>, <fpage>7267</fpage>&#x02013;<lpage>7283</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00407</pub-id>.<pub-id pub-id-type="pmid">28809565</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Meini</surname><given-names>M.-R.</given-names></name>; <name><surname>Llarrull</surname><given-names>L. I.</given-names></name>; <name><surname>Vila</surname><given-names>A. J.</given-names></name> (<year>2014</year>) <article-title>Evolution of Metallo-&#x003b2;-lactamases:
Trends Revealed by Natural Diversity and in vitro Evolution</article-title>. <source>Antibiotics</source>
<volume>3</volume>, <fpage>285</fpage>&#x02013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.3390/antibiotics3030285</pub-id>.<pub-id pub-id-type="pmid">25364574</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Copeland</surname><given-names>R. A.</given-names></name> (<year>2005</year>) <article-title>Evaluation
of enzyme inhibitors in drug discovery. A guide for medicinal chemists
and pharmacologists</article-title>. <source>Methods Biochem. Anal.</source>
<volume>46</volume>, <fpage>1</fpage>&#x02013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1002/9781118540398</pub-id>.<pub-id pub-id-type="pmid">16350889</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Siemann</surname><given-names>S.</given-names></name>; <name><surname>Clarke</surname><given-names>A. J.</given-names></name>; <name><surname>Viswanatha</surname><given-names>T.</given-names></name>; <name><surname>Dmitrienko</surname><given-names>G. I.</given-names></name> (<year>2003</year>) <article-title>Thiols
as classical and slow-binding inhibitors of IMP-1 and other binuclear
metallo-beta-lactamases</article-title>. <source>Biochemistry</source>
<volume>42</volume>, <fpage>1673</fpage>&#x02013;<lpage>1683</lpage>. <pub-id pub-id-type="doi">10.1021/bi027072i</pub-id>.<pub-id pub-id-type="pmid">12578382</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Badarau</surname><given-names>A.</given-names></name>; <name><surname>Llinas</surname><given-names>A.</given-names></name>; <name><surname>Laws</surname><given-names>A. P.</given-names></name>; <name><surname>Damblon</surname><given-names>C.</given-names></name>; <name><surname>Page</surname><given-names>M. I.</given-names></name> (<year>2005</year>) <article-title>Inhibitors
of metallo-beta-lactamase generated from beta-lactam antibiotics</article-title>. <source>Biochemistry</source>
<volume>44</volume>, <fpage>8578</fpage>&#x02013;<lpage>8589</lpage>. <pub-id pub-id-type="doi">10.1021/bi050302j</pub-id>.<pub-id pub-id-type="pmid">15952764</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Mondal</surname><given-names>J.</given-names></name>; <name><surname>Morrone</surname><given-names>J. A.</given-names></name>; <name><surname>Berne</surname><given-names>B. J.</given-names></name> (<year>2013</year>) <article-title>How hydrophobic drying forces impact
the kinetics of molecular recognition</article-title>. <source>Proc.
Natl. Acad. Sci. U. S. A.</source>
<volume>110</volume>, <fpage>13277</fpage>&#x02013;<lpage>13282</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1312529110</pub-id>.<pub-id pub-id-type="pmid">23901110</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Copeland</surname><given-names>R. A.</given-names></name> (<year>2010</year>) <article-title>The dynamics
of drug-target interactions: drug-target residence time and its impact
on efficacy and safety</article-title>. <source>Expert Opin. Drug Discovery</source>
<volume>5</volume>, <fpage>305</fpage>&#x02013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1517/17460441003677725</pub-id>.</mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Copeland</surname><given-names>R. A.</given-names></name>; <name><surname>Pompliano</surname><given-names>D. L.</given-names></name>; <name><surname>Meek</surname><given-names>T. D.</given-names></name> (<year>2006</year>) <article-title>Drug-target residence time and its
implications for lead optimization</article-title>. <source>Nat. Rev.
Drug Discovery</source>
<volume>5</volume>, <fpage>730</fpage>&#x02013;<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2082</pub-id>.<pub-id pub-id-type="pmid">16888652</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Dahl</surname><given-names>G.</given-names></name>; <name><surname>Akerud</surname><given-names>T.</given-names></name> (<year>2013</year>) <article-title>Pharmacokinetics and
the drug-target residence time
concept</article-title>. <source>Drug Discovery Today</source>
<volume>18</volume>, <fpage>697</fpage>&#x02013;<lpage>707</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2013.02.010</pub-id>.<pub-id pub-id-type="pmid">23500610</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Walkup</surname><given-names>G. K.</given-names></name>; <name><surname>You</surname><given-names>Z.</given-names></name>; <name><surname>Ross</surname><given-names>P. L.</given-names></name>; <name><surname>Allen</surname><given-names>E. K.</given-names></name>; <name><surname>Daryaee</surname><given-names>F.</given-names></name>; <name><surname>Hale</surname><given-names>M. R.</given-names></name>; <name><surname>O&#x02019;Donnell</surname><given-names>J.</given-names></name>; <name><surname>Ehmann</surname><given-names>D. E.</given-names></name>; <name><surname>Schuck</surname><given-names>V. J.</given-names></name>; <name><surname>Buurman</surname><given-names>E. T.</given-names></name>; <name><surname>Choy</surname><given-names>A. L.</given-names></name>; <name><surname>Hajec</surname><given-names>L.</given-names></name>; <name><surname>Murphy-Benenato</surname><given-names>K.</given-names></name>; <name><surname>Marone</surname><given-names>V.</given-names></name>; <name><surname>Patey</surname><given-names>S. A.</given-names></name>; <name><surname>Grosser</surname><given-names>L. A.</given-names></name>; <name><surname>Johnstone</surname><given-names>M.</given-names></name>; <name><surname>Walker</surname><given-names>S. G.</given-names></name>; <name><surname>Tonge</surname><given-names>P. J.</given-names></name>; <name><surname>Fisher</surname><given-names>S. L.</given-names></name> (<year>2015</year>) <article-title>Translating slow-binding
inhibition kinetics into cellular and in vivo effects</article-title>. <source>Nat. Chem. Biol.</source>
<volume>11</volume>, <fpage>416</fpage>&#x02013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1796</pub-id>.<pub-id pub-id-type="pmid">25894085</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Papagiannitsis</surname><given-names>C. C.</given-names></name>; <name><surname>Izdebski</surname><given-names>R.</given-names></name>; <name><surname>Baraniak</surname><given-names>A.</given-names></name>; <name><surname>Fiett</surname><given-names>J.</given-names></name>; <name><surname>Herda</surname><given-names>M.</given-names></name>; <name><surname>Hrabak</surname><given-names>J.</given-names></name>; <name><surname>Derde</surname><given-names>L. P.</given-names></name>; <name><surname>Bonten</surname><given-names>M. J.</given-names></name>; <name><surname>Carmeli</surname><given-names>Y.</given-names></name>; <name><surname>Goossens</surname><given-names>H.</given-names></name>; <name><surname>Hryniewicz</surname><given-names>W.</given-names></name>; <name><surname>Brun-Buisson</surname><given-names>C.</given-names></name>; <name><surname>Gniadkowski</surname><given-names>M.</given-names></name> (<year>2015</year>) <article-title>Survey of metallo-beta-lactamase-producing Enterobacteriaceae
colonizing patients in European ICUs and rehabilitation units, 2008&#x02013;11</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>70</volume>, <fpage>1981</fpage>&#x02013;<lpage>1988</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkv055</pub-id>.<pub-id pub-id-type="pmid">25759034</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="book" id="cit75"><person-group person-group-type="allauthors"><collab>EUCAST</collab></person-group> (<year>2017</year>) <source>The European Committee
on Antimicrobial
Susceptibility Testing. Breakpoint tables for interpretation of MICs
and zone diameters</source>, version 7.1 (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.eucast.org">http://www.eucast.org</uri>).</mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Walsh</surname><given-names>F.</given-names></name> (<year>2007</year>) <article-title>Doripenem:
A new carbapenem antibiotic a review of comparative antimicrobial
and bactericidal activities</article-title>. <source>Ther. Clin. Risk
Manage.</source>
<volume>3</volume>, <fpage>789</fpage>&#x02013;<lpage>794</lpage>.</mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Looney</surname><given-names>W.
J.</given-names></name>; <name><surname>Narita</surname><given-names>M.</given-names></name>; <name><surname>Muhlemann</surname><given-names>K.</given-names></name> (<year>2009</year>) <article-title>Stenotrophomonas maltophilia: an
emerging opportunist human pathogen</article-title>. <source>Lancet
Infect. Dis.</source>
<volume>9</volume>, <fpage>312</fpage>&#x02013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(09)70083-0</pub-id>.<pub-id pub-id-type="pmid">19393961</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Waters</surname><given-names>V.</given-names></name>; <name><surname>Yau</surname><given-names>Y.</given-names></name>; <name><surname>Prasad</surname><given-names>S.</given-names></name>; <name><surname>Lu</surname><given-names>A.</given-names></name>; <name><surname>Atenafu</surname><given-names>E.</given-names></name>; <name><surname>Crandall</surname><given-names>I.</given-names></name>; <name><surname>Tom</surname><given-names>S.</given-names></name>; <name><surname>Tullis</surname><given-names>E.</given-names></name>; <name><surname>Ratjen</surname><given-names>F.</given-names></name> (<year>2011</year>) <article-title>Stenotrophomonas maltophilia in cystic
fibrosis: serologic response and effect on lung disease</article-title>. <source>Am. J. Respir. Crit. Care Med.</source>
<volume>183</volume>, <fpage>635</fpage>&#x02013;<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201009-1392OC</pub-id>.<pub-id pub-id-type="pmid">20889901</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Freedman</surname><given-names>L. D.</given-names></name>; <name><surname>Doak</surname><given-names>G. O.</given-names></name> (<year>1957</year>) <article-title>The Preparation
And Properties Of Phosphonic Acids,</article-title>. <source>Chem. Rev.</source>
<volume>57</volume>, <fpage>479</fpage>&#x02013;<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1021/cr50015a003</pub-id>.</mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Yu</surname><given-names>H.</given-names></name>; <name><surname>Kuhne</surname><given-names>R.</given-names></name>; <name><surname>Ebert</surname><given-names>R. U.</given-names></name>; <name><surname>Schuurmann</surname><given-names>G.</given-names></name> (<year>2010</year>) <article-title>Comparative
analysis of QSAR models for predicting pK(a) of organic oxygen acids
and nitrogen bases from molecular structure</article-title>. <source>J. Chem. Inf. Model.</source>
<volume>50</volume>, <fpage>1949</fpage>&#x02013;<lpage>1960</lpage>. <pub-id pub-id-type="doi">10.1021/ci100306k</pub-id>.<pub-id pub-id-type="pmid">21033677</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name><surname>Giamarellou</surname><given-names>H.</given-names></name>; <name><surname>Antoniadou</surname><given-names>A.</given-names></name> (<year>2001</year>) <article-title>Antipseudomonal antibiotics</article-title>. <source>Med. Clin. North Am.</source>
<volume>85</volume>, <fpage>19</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/S0025-7125(05)70303-5</pub-id>.<pub-id pub-id-type="pmid">11190351</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Garuti</surname><given-names>L.</given-names></name>; <name><surname>Ferranti</surname><given-names>A.</given-names></name>; <name><surname>Roberti</surname><given-names>M.</given-names></name>; <name><surname>Katz</surname><given-names>E.</given-names></name>; <name><surname>Budriesi</surname><given-names>R.</given-names></name>; <name><surname>Chiarini</surname><given-names>A.</given-names></name> (<year>1992</year>) <article-title>Synthesis and biological evaluation
of some new phosphonates</article-title>. <source>Pharmazie</source>
<volume>47</volume>, <fpage>295</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">1518889</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name><surname>Martinez</surname><given-names>C. R.</given-names></name>; <name><surname>Iverson</surname><given-names>B. L.</given-names></name> (<year>2012</year>) <article-title>Rethinking the term
&#x02033;pi-stacking&#x02033;</article-title>. <source>Chemical Science</source>
<volume>3</volume>, <fpage>2191</fpage>&#x02013;<lpage>2201</lpage>. <pub-id pub-id-type="doi">10.1039/c2sc20045g</pub-id>.</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name><surname>Gardonio</surname><given-names>D.</given-names></name>; <name><surname>Siemann</surname><given-names>S.</given-names></name> (<year>2009</year>) <article-title>Chelator-facilitated
chemical modification of IMP-1
metallo-beta-lactamase and its consequences on metal binding</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>381</volume>, <fpage>107</fpage>&#x02013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.02.021</pub-id>.<pub-id pub-id-type="pmid">19351604</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name><surname>Toney</surname><given-names>J. H.</given-names></name>; <name><surname>Hammond</surname><given-names>G. G.</given-names></name>; <name><surname>Fitzgerald</surname><given-names>P. M.</given-names></name>; <name><surname>Sharma</surname><given-names>N.</given-names></name>; <name><surname>Balkovec</surname><given-names>J. M.</given-names></name>; <name><surname>Rouen</surname><given-names>G. P.</given-names></name>; <name><surname>Olson</surname><given-names>S. H.</given-names></name>; <name><surname>Hammond</surname><given-names>M. L.</given-names></name>; <name><surname>Greenlee</surname><given-names>M. L.</given-names></name>; <name><surname>Gao</surname><given-names>Y. D.</given-names></name> (<year>2001</year>) <article-title>Succinic acids as
potent inhibitors of plasmid-borne
IMP-1 metallo-beta-lactamase</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>, <fpage>31913</fpage>&#x02013;<lpage>31918</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M104742200</pub-id>.<pub-id pub-id-type="pmid">11390410</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name><surname>Payne</surname><given-names>D. J.</given-names></name>; <name><surname>Hueso-Rodr&#x000ed;guez</surname><given-names>J. A.</given-names></name>; <name><surname>Boyd</surname><given-names>H.</given-names></name>; <name><surname>Concha</surname><given-names>N. O.</given-names></name>; <name><surname>Janson</surname><given-names>C. A.</given-names></name>; <name><surname>Gilpin</surname><given-names>M.</given-names></name>; <name><surname>Bateson</surname><given-names>J. H.</given-names></name>; <name><surname>Cheever</surname><given-names>C.</given-names></name>; <name><surname>Niconovich</surname><given-names>N. L.</given-names></name>; <name><surname>Pearson</surname><given-names>S.</given-names></name>; <name><surname>Rittenhouse</surname><given-names>S.</given-names></name>; <name><surname>Tew</surname><given-names>D.</given-names></name>; <name><surname>D&#x000ed;ez</surname><given-names>E.</given-names></name>; <name><surname>P&#x000e9;rez</surname><given-names>P.</given-names></name>; <name><surname>de la Fuente</surname><given-names>J.</given-names></name>; <name><surname>Rees</surname><given-names>M.</given-names></name>; <name><surname>Rivera-Sagredo</surname><given-names>A.</given-names></name> (<year>2002</year>) <article-title>Identification
of a Series of Tricyclic
Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-&#x003b2;-Lactamases</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>46</volume>, <fpage>1880</fpage>&#x02013;<lpage>1886</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.46.6.1880-1886.2002</pub-id>.<pub-id pub-id-type="pmid">12019104</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name><surname>Costello</surname><given-names>A.</given-names></name>; <name><surname>Periyannan</surname><given-names>G.</given-names></name>; <name><surname>Yang</surname><given-names>K. W.</given-names></name>; <name><surname>Crowder</surname><given-names>M. W.</given-names></name>; <name><surname>Tierney</surname><given-names>D. L.</given-names></name> (<year>2006</year>) <article-title>Site-selective
binding of Zn(II) to metallo-beta-lactamase L1 from Stenotrophomonas
maltophilia</article-title>. <source>JBIC, J. Biol. Inorg. Chem.</source>
<volume>11</volume>, <fpage>351</fpage>&#x02013;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1007/s00775-006-0083-z</pub-id>.<pub-id pub-id-type="pmid">16489411</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name><surname>Griffin</surname><given-names>D. H.</given-names></name>; <name><surname>Richmond</surname><given-names>T. K.</given-names></name>; <name><surname>Sanchez</surname><given-names>C.</given-names></name>; <name><surname>M&#x000f6;ller</surname><given-names>A. J.</given-names></name>; <name><surname>Breece</surname><given-names>R. M.</given-names></name>; <name><surname>Tierney</surname><given-names>D. L.</given-names></name>; <name><surname>Bennett</surname><given-names>B.</given-names></name>; <name><surname>Crowder</surname><given-names>M. W.</given-names></name> (<year>2011</year>) <article-title>Structural
and kinetic studies on metallo-beta-lactamase IMP-1</article-title>. <source>Biochemistry</source>
<volume>50</volume>, <fpage>9125</fpage>&#x02013;<lpage>9134</lpage>. <pub-id pub-id-type="doi">10.1021/bi200839h</pub-id>.<pub-id pub-id-type="pmid">21928807</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name><surname>Calvopina</surname><given-names>K.</given-names></name>; <name><surname>Umland</surname><given-names>K. D.</given-names></name>; <name><surname>Rydzik</surname><given-names>A. M.</given-names></name>; <name><surname>Hinchliffe</surname><given-names>P.</given-names></name>; <name><surname>Brem</surname><given-names>J.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Schofield</surname><given-names>C. J.</given-names></name>; <name><surname>Avison</surname><given-names>M. B.</given-names></name> (<year>2016</year>) <article-title>Sideromimic Modification of Lactivicin Dramatically
Increases Potency against Extensively Drug-Resistant Stenotrophomonas
maltophilia Clinical Isolates</article-title>. <source>Antimicrob. Agents
Chemother.</source>
<volume>60</volume>, <fpage>4170</fpage>&#x02013;<lpage>4175</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00371-16</pub-id>.<pub-id pub-id-type="pmid">27139464</pub-id></mixed-citation></ref></ref-list></back></article>
